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Abstract
Introduction: Previous studies have demonstrated that common breast cancer susceptibility alleles are
differentially associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. It is currently unknown
how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers
defined by estrogen (ER) or progesterone receptor (PR) status of the tumour.
Methods: We used genotype data on up to 11,421 BRCA1 and 7,080 BRCA2 carriers, of whom 4,310 had been
affected with breast cancer and had information on either ER or PR status of the tumour, to assess the associations
of 12 loci with breast cancer tumour characteristics. Associations were evaluated using a retrospective cohort
approach.
Results: The results suggested stronger associations with ER-positive breast cancer than ER-negative for 11 loci in
both BRCA1 and BRCA2 carriers. Among BRCA1 carriers, single nucleotide polymorphism (SNP) rs2981582 (FGFR2)
exhibited the biggest difference based on ER status (per-allele hazard ratio (HR) for ER-positive = 1.35, 95% CI: 1.17
to 1.56 vs HR = 0.91, 95% CI: 0.85 to 0.98 for ER-negative, P-heterogeneity = 6.5 × 10-6). In contrast, SNP rs2046210
at 6q25.1 near ESR1 was primarily associated with ER-negative breast cancer risk for both BRCA1 and BRCA2 carriers.
In BRCA2 carriers, SNPs in FGFR2, TOX3, LSP1, SLC4A7/NEK10, 5p12, 2q35, and 1p11.2 were significantly associated
with ER-positive but not ER-negative disease. Similar results were observed when differentiating breast cancer cases
by PR status.
Conclusions: The associations of the 12 SNPs with risk for BRCA1 and BRCA2 carriers differ by ER-positive or ER-
negative breast cancer status. The apparent differences in SNP associations between BRCA1 and BRCA2 carriers, and
non-carriers, may be explicable by differences in the prevalence of tumour subtypes. As more risk modifying
variants are identified, incorporating these associations into breast cancer subtype-specific risk models may improve
clinical management for mutation carriers.
Introduction
Germline mutations in BRCA1 and BRCA2 confer high
risks of breast, ovarian and other cancers [1-3] and
account for 15 to 20% of the excess familial risk of
breast cancer among first degree relatives [4,5]. Breast
cancer risks for BRCA1 and BRCA2 mutation carriers
have been estimated to range between 40 and 87% by
age 70 [6-12] with population-based estimates tending
to be lower than estimates based on families with multi-
ple affected individuals [6,8]. Moreover, breast cancer
risks for mutation carriers were found to vary according
to the age at diagnosis and the type of cancer of the
index patient involved in the family ascertainment
[6,7,11]. Such evidence suggests that genetic or other
risk factors that cluster in families modify the cancer
risks conferred by BRCA1 and BRCA2 mutations.
A substantial body of work indicates that tumours
arising in patients with germline BRCA1 mutations are
morphologically and genetically distinct from those aris-
ing in carriers of BRCA2 mutations and from tumours
in patients lacking mutations. In gene expression stu-
dies, BRCA1-associated tumours are often classified as
basal subtype tumours [13,14]. This is reflected in their
higher grade, and morphologic features including lym-
phocytic infiltrate, pushing margins and syncytial
growth. Being basal-like they express several markers
that are normally expressed in the basal/myoepithelial
cells of the breast, including stratified epithelial cytoker-
atins 5/6, 14 and 17. BRCA1-associated tumours are
more likely to be estrogen receptor (ER), progesterone
receptor (PR) and HER2 negative and to harbor muta-
tions in the TP53 gene than age-matched sporadic
breast cancers [15,16]. BRCA2-associated tumours are
also predominantly high-grade invasive ductal carcino-
mas of no special type but they often demonstrate a
luminal phenotype despite their high histologic grade
[13,17]. Adjusting for grade, BRCA2-associated tumours
are more often ER-positive and are less likely, compared
with controls, to express the basal cytokeratin CK5 or to
overexpress HER2/neu protein [17].
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Establishing the estrogen receptor status of a breast
cancer (positive or negative) reflects a major subdivision
in breast cancer type (at least five major sub-types are
recognized) and it is becoming clear that the risk factors
associated with breast cancer, both genetic and epide-
miological, differ according to sub-type. Genome-wide
association studies (GWAS) in breast cancer have iden-
tified several common alleles (single nucleotide poly-
morphisms (SNPs)) associated with an increased risk of
breast cancer in the general population [18-25]. Many of
these SNPs are associated with risk for ER-positive
breast cancer, fewer have so far been associated with
ER-negative breast cancer risk [26,27].
Known risk breast cancer susceptibility alleles have
been genotyped in a large series of female BRCA1 and
BRCA2 mutation carriers assembled by the Consortium
of Investigators of Modifiers of BRCA1/2 (CIMBA) to
evaluate their associations with risk of breast cancer for
mutation carriers. Of the 12 SNPs (rs2981582 in FGFR2,
rs3803662 in TOX3/TNRC9, rs889312 in MAP3K1,
rs13281615 at 8q24, rs381798 in LSP1, rs13387042 at
2q35, rs4973768 in SLC4A7/NEK10, rs10941679 at 5p12,
rs6504950 in STXBP4/COX11, rs999737/rs10483813 in
RAD51L1, rs2046210 at 6q25.1 and rs11249433 at
1p11.2) investigated so far, eight were associated with
breast cancer risk for BRCA2 carriers (all but SNPs at
8q24, RAD51L1, 6q25.1 and STXBP4/COX11), whereas
only three SNPs (6q25.1, TOX3/TNRC9 and 2q35) were
associated with risk for BRCA1 mutation carriers [28-31].
Work from the Breast Cancer Association Consortium
and subsequent studies have demonstrated differences in
the associations between these susceptibility loci and
tumour characteristics in the general population [27,32].
These results suggest that the observed differences in the
associations between BRCA1 and BRCA2 mutation car-
riers may reflect differences in the distribution of tumour
characteristics in mutation carriers. It is currently unclear
whether these polymorphisms are associated with differ-
ent tumour characteristics within BRCA1 and BRCA2
mutation carriers.
As an adjunct to predictive testing for a high risk
BRCA1 or BRCA2 gene mutation, more individualized
risk estimates that take into account additional genetic
and environmental modifiers will require a more
detailed understanding of how these various risk factors
interact. Understanding whether common genetic var-
iants modify the risks of developing ER-positive or ER-
negative breast cancer in BRCA1 and BRCA2 mutation
carriers could potentially influence the clinical manage-
ment of these individuals. For example, knowing that a
BRCA1 mutation carrier is more likely to develop ER-
positive breast cancer (than most BRCA1 mutation car-
riers), may influence the choice of management strate-
gies, such as chemoprevention. In this study, we used
data from the CIMBA consortium to evaluate the asso-
ciations between the 12 common breast cancer suscept-
ibility alleles and risk for breast cancer defined by ER
and PR status.
Materials and methods
Subjects
Subjects were BRCA1 and BRCA2 mutation carriers
recruited by 36 study centres in Europe, North America
and Australia (Table 1). All carriers participated in clini-
cal or research studies at the host institutions, which
have been approved by local ethics committees (list pro-
vided in Additional file 1, Table S1). Each committee
granted approval for access and use of the medical
records for the present analyses.
The large majority of carriers were recruited through
cancer genetics clinics offering genetic testing, and
enrolled into national or regional studies. Eligibility to
participate in CIMBA is restricted to female carriers of
pathogenic BRCA1 or BRCA2 mutations who were 18
years old or older at recruitment. Information collected
included the year of birth; mutation description, includ-
ing nucleotide position and base change; age at last fol-
low-up; ages at breast and ovarian cancer diagnoses; and
age or date at bilateral prophylactic mastectomy. Infor-
mation was also available on the country of residence.
Related individuals were identified through a unique
family identifier. Women were included in the analysis if
they carried mutations that were pathogenic according
to generally recognized criteria. Only studies that pro-
vided tumour pathology information and had genotype
information were included in the analysis. However, to
maximise the available information, genotyped mutation
carriers within those studies missing information on
tumour characteristics were included in the analysis and
their disease subtype was assumed to be missing at ran-
dom (see statistical methods for details). Further details
about the CIMBA initiative can be found elsewhere [33].
Tumour pathology data collection
Tumour pathology data were amalgamated from a range
of sources, specifically patient pathology reports, medical
records, pathology review data, tumour registry records
and results from tissue microarrays. Estrogen and pro-
gesterone receptor status was provided as negative or
positive, with supplementary immunohistochemistry
scoring data and methodology provided when available.
Based on definitions supplied, most centres employed a
cut off of ≥10% of tumour cells stained positive to
define receptor positivity. To ensure consistency across
studies, when information on the proportion of cells
stained was available, we used the same cut-off to define
ER and PR positive tumours. For a small number of
cases where composite scoring methods based on the
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proportion and intensity of staining were available
(Allred score, Remmele score and H-score), widely-
accepted cut-offs were used (Additional file 1, Table S2).
Consistency checks were performed to validate receptor
data against supplementary scoring information if
provided.
Genotyping
This analysis included genotype data on 12 SNPs that
had been previously assessed for their associations
with the overall risk of breast cancer for BRCA1 and
BRCA2 mutation carriers in CIMBA. Genotyping was
performed using either the iPLEX or Taqman plat-
forms and has been described in detail in the previous
reports [28-31]. To ensure genotyping consistency, all
genotyping centres were required to adhere to the
CIMBA genotyping quality control criteria which are
described in detail online [34]. The 12 SNPs genotyped
were rs2981582 in FGFR2, rs3803662 in TOX3/
TNRC9, rs889312 in MAP3K1, rs3817198 in LSP1,
rs13387042 at 2q35, rs13281615 at 8q24, rs4973768
near SLC4A7/NEK10, rs6504950 in the STXBP4/
COX11 region, rs2046210 near ESR1 at 6q25.1 and
rs11249433 at 1p11.2. A Taqman assay could not be
adequately designed for SNP rs999737 in the RAD51L1
region and studies using this platform genotyped the
surrogate SNP rs10483813 (pair-wise r2 = 1 with
rs999737 based on HapMap CEU data). Data for these
two SNPs were combined and treated as a single locus
in the analysis of associations.
Statistical analysis
The aim of this study was to evaluate the associations
between each genotype and breast cancer subtypes
defined by tumour characteristics in BRCA1 and BRCA2
mutation carriers separately. The phenotype of each
individual was defined by the age at diagnosis of breast
cancer and its subtype or by age at last follow-up. Indi-
viduals were censored at the age of the first breast can-
cer diagnosis, ovarian cancer diagnosis, or bilateral
prophylactic mastectomy or the age at last observation.
Mutation carriers censored at ovarian cancer diagnosis
were considered unaffected.
The analysis of risk modifiers in BRCA1 and BRCA2
mutation carriers is complicated by the fact that muta-
tion carriers are not randomly sampled with respect to
their disease status. Many carriers are sampled through
families seen in genetic clinics. The first tested indivi-
dual in a family is usually someone diagnosed with can-
cer at a relatively young age. Such study designs,
therefore, tend to lead to an over-sampling of affected
individuals, and standard analytical methods like Cox
regression or case-control analysis may lead to biased
estimates of the risk ratios [35]. This can be illustrated
by considering an individual affected at age t. In a stan-
dard analysis of a cohort study or a case-control analy-
sis, the SNP genotype for the individual will be
compared with those of all individuals at risk at age t or
in a case-control analysis, with controls randomly
sampled from all possible at risk individuals. This analy-
sis leads to consistent estimates of the hazard ratio or
Table 1 Number of mutation carriers by country grouping affection status and tumour marker characteristics
Country Group BRCA1 BRCA2 Unaffected Breast Cancer ER- ER+ PR- PR+
Austria1 465 179 318 326 76 51 76 44
Australia2 660 552 541 671 235 200 297 121
Canada3 443 358 386 415 107 70 89 68
Denmark4 507 319 463 363 98 93 79 45
France-Belgium-Spain5 1,673 1,256 1,217 1,712 140 165 1,661 127
Finland6 103 105 91 117 59 54 74 39
Germany7 1,231 589 648 1,172 443 336 457 311
Iceland8 0 135 24 111 21 57 18 57
Italy9 994 666 686 974 203 251 231 216
Latvia-Lithuania-Russia10 190 0 79 111 21 6 18 7
Sweden11 537 177 396 318 86 54 89 50
Netherlands12 804 319 611 512 72 41 69 29
UK-Eire13 1,107 866 1,008 965 268 239 175 104
USA14 2,707 1559 2,118 2048 482 366 512 297
Total 11,421 7,080 8,686 9,815 2,311 1,983 2,345 1,515
Studies in country groups:1:MUV; 2:BCFR/KCONFAB; 3:OCGN/BCFR/INHERIT; 4:CBCS/OUH; 5: GEMO/CNIO/HCSC/ICO/MOD-SQUAD; 6:HEBCS; 7:GC-HBOC/DKFZ; 8:
ILUH; 9:CONSIT-TEAM/IOVHBOCS/PBCS; 10: NNPIO/BFBOCC; 11: SWE-BRCA; 12: HEBON; 13:EMBRACE/UKGRFOCR; 14:FCCC/GEMO/GEORGETOWN/MAGIC/MAYO/
MSKCC/NCI/OSU-CCG/UCI/UCSF/UKGRFOCR/UPENN/WCRI
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odds ratio estimates. However, in the present design,
mutation carriers are already selected on the basis of
disease status (where affected individuals are over-
sampled). If standard cohort analysis were applied to
these data, it would lead to affected individuals at age t
being compared to unaffected carriers selected on the
basis of their future disease status. If the genotype is
associated with the disease, the risk estimate will be
biased to zero because too many affected individuals (in
whom the at-risk genotype is overrepresented) are
included in the comparison group. Simulation studies
have shown that this effect can be quite marked [35].
To address this, a retrospective likelihood approach was
previously proposed, which models the observed geno-
types conditional on the disease phenotypes [36]. For
the current analyses we have extended this method to
model the simultaneous effect of each SNP on more
than one tumour subtype. We briefly describe this
method for the analysis of associations with ER-positive
and ER-negative breast cancer, but the same principles
apply for the analysis of associations with other tumour
characteristics.
We modelled the likelihood of the observed genotypes
and tumour subtype conditional on the disease status,
that is:
n∏
i=1
P
(
gi, di|y(ti)
)
=
n∏
i
P
(
(y(ti), di|gi)
)
P(gi)
P
(
y(ti)
) (1)
Where y(ti) is the disease phenotype for individual i at
censoring age ti (breast cancer at age ti or unaffected at
age ti), di is the ER status (0 = negative, 1 = positive)
and gi the observed genotype of individual i (gi = 0, 1 or
2 minor alleles) and n the number of subjects in the
analysis. To allow for tumour characteristics we
assumed that breast cancer consists of different disease
subtypes, such that the total breast cancer incidence at
age ti, l(ti), is the sum of the disease incidence for the
subtypes, that is l(ti) = v(ti) + μ(ti), where v(ti) is the
incidence for ER-negative disease and μ(ti) is the inci-
dence of ER-positive disease. We assumed that the sub-
type-specific incidences depend on the underlying
genotype through a Cox-proportional hazards model:
ν(ti) = ν0(ti) exp(β tzgi) and
μ(ti) = μ0(ti) exp(γ tzgi)where v0(ti) and μ0(ti) and are
the baseline incidences for disease subtypes (ER-negative
and ER-positive respectively), zgi is the genotype vector
for individual i and b and g are the subtype specific gen-
otype log-risk ratios (for ER-negative and ER-positive
breast cancer respectively). The probabilities of develop-
ing ER-positive and ER-negative breast cancer condi-
tional on the underlying genotype were assumed to be
independent. We further assumed that, if tumour
subtype is unknown, the information is missing at ran-
dom with respect to genotype. Then for each individual:
P
(
(y(ti), di|gi)
)
=
=
(
ν0(ti) exp(β tzgi)
)Oi(1−di) × (μ0(ti) exp(γ tzgi))Oidi×
exp
(
−
ti−1∑
u=0
(
μ0(u) exp
(
γ tzgi
)
+ ν0(u) exp
(
β tzgi
)))
if di = 0, 1
=
(
μ0(ti) exp(γ tzgi) + ν0(t) exp(β
tzgi)
)Oi×
exp
(
−
ti−1∑
u=0
(
μ0(u) exp
(
γ tzgi
)
+ ν0(u) exp
(
β tzgi
)))
if di = unknown
were Oi = 0 if unaffected and Oi = 1 if affected. Thus,
the above formulation allows use of all mutation carriers
irrespective of whether the tumour subtype is observed
or not. The baseline incidences for each disease subtype
(v0(ti) and μ0(ti)) are unknown. However, it is possible
to solve for those recursively by constraining the overall
breast cancer incidence for mutation carriers l(t), to
agree with external estimates as previously demonstrated
[37,38] and by imposing a further constraint on the ratio
of the observed ER-positive to ER-negative breast can-
cers in each age group:
P(ERpositive at age t)
P(ERnegative at age t)
=
π+(t)
π−(t)
=
=
∑
g
P(g)μ0(t) exp(γ tzg) exp
(
−
t−1∑
u=0
(μ0(u) exp(γ tzg) + ν0(u) exp(β tzg))
)
∑
g
P(g)v0(t) exp(β tzg) exp
(
−
t−1∑
u=0
(μ0(u) exp(γ tzg) + ν0(u) exp(β tzg))
)
The likelihood in equation 1 can then be maximised
jointly over the log-risk ratios b and g, genotype fre-
quencies P(g) and the age and subtype-specific frequen-
cies π+(t) and π-(t) This likelihood is based on the
assumption that the ascertainment of mutation carriers
is dependent on the overall disease phenotype (breast
cancer) but not on tumour subtypes. This allows the
subtype frequencies π+(t) and π-(t) to be estimated
within the dataset. Relaxing this assumption and condi-
tioning also on tumour subtype requires external esti-
mates for the age and subtype-specific frequencies π+(t)
and π-(t).
The effect of each SNP was modelled either as a per-
allele HR (multiplicative model) or as separate HRs for
heterozygotes and homozygotes, and these were esti-
mated on the logarithmic scale. Heterogeneity in the
hazard ratios between tumour subtypes was examined
by fitting models where v(ti) = v0(ti) exp (b1g) and μ(ti)
= μ0(ti) exp (b1 + b2)g) with g = 0,1 and 2 (for 0, 1, 2
copies of the minor allele respectively) and testing for b2
= 0. Analyses were carried out with the pedigree-analy-
sis software MENDEL [39]. All analyses were stratified
by country of residence and used calendar-year- and
cohort-specific cancer incidences for BRCA1 and
BRCA2 [40]. For this purpose, a stratified version of the
retrospective likelihood (equation 1) was derived as
described previously [36]. Countries with small numbers
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of mutation carriers were grouped together. We used a
robust variance-estimation approach to allow for the
non-independence among related mutation carriers [41].
Predicted breast cancer risks by ER status
Based on our results we computed the predicted abso-
lute risk of developing ER-negative and ER-positive
breast cancer for BRCA1 and BRCA2 mutation carriers
by the combined 12 SNP profile. For each individual we
derived an empirical score, based on the per-allele log-
relative hazard estimates for each genotype, which was
of the form
12∑
j=1
βjgjwhere bj is the per-allele log-hazard
estimate for locus j and gj is the genotype at the same
locus (taking values 0, 1 and 2). This assumes a multi-
plicative model for the combined SNP associations. This
is a reasonable assumption given that previous analyses
found no evidence of departure from the multiplicative
model [35]. Scores were calculated for ER-positive and
ER-negative disease, separately for BRCA1and BRCA2
mutation carriers. The empirical distribution of the
derived score was then used to compute the subtype
specific incidence associated with each multilocus geno-
type as described previously [31]. We reported the abso-
lute risks of developing ER-specific breast cancer at the
5th, 50th and 95th percentiles of the empirical distribu-
tion of the SNP profile.
Results
A total of 11,421 BRCA1 and 7,080 BRCA2 mutation
carriers from 36 studies had been successfully genotyped
for at least one of the12 SNPs and were eligible for
inclusion in these analyses. 9,815 BRCA1 and BRCA2
mutation carriers were censored at a first invasive breast
cancer diagnosis, of whom 4,310 had information on
either ER or PR (Table 1).
Associations with ER status - BRCA1 mutation carriers
There were significant differences in the HR for ER-
positive and ER-negative disease for BRCA1 mutation
carriers for two SNPs (Table 2). The FGFR2 SNP
rs2981582 exhibited the clearest difference with a strong
association for ER-positive disease but not ER-negative
disease (per allele HR = 1.35, 95% CI: 1.17 to 1.56, for
ER-positive compared with HR = 0.91, 95% CI: 0.85 to
0.98 for ER-negative, P-heterogeneity = 6.5 × 10-6). The
SLC4A7/NEK10 SNP rs4973768 also exhibited a similar
pattern (ER-positive: per-allele HR = 1.17, 95% CI: 1.03
to 1.133, compared with ER-negative: per-allele HR =
0.99, 95% CI: 0.93 to 1.06, P-heterogeneity = 0.027).
Although there was no significant evidence of differ-
ences between the HRs for ER-positive and ER-negative
breast cancer, the TOX3/TNRC9 SNP rs3803662 was
significantly associated with the risk of ER-positive dis-
ease (per-allele HR = 1.25, 95% CI: 1.06 to .46, P-trend
= 0.0062) but not with risk for ER-negative breast can-
cer (per-allele HR = 1.05, 95% CI: 0.97 to 1.13, P-trend
= 0.21). LSP1 SNP rs3817198 was associated with the
risk of ER-negative breast cancer (per-allele HR = 1.07,
95% CI: 1.00 to 1.07, P-trend = 0.047) but not with risk
of ER-positive breast cancer (per-allele HR = 1.07, 95%
CI: 0.93 to 1.22, P-trend = 0.33, P-het = 0.98). The
6q25.1 SNP rs2046210 near ESR1 was associated with
the risk for both ER-negative (per-allele HR = 1.19, 95%
CI: 1.11 to 1.27, P-trend = 2.4 × 10-7) and ER-positive
(per-allele HR = 1.14, 95% CI: 1.01 to 1.30, P-trend =
0.043) breast cancer. There was no significant evidence
of association with either ER-negative or ER-positive
breast cancer for any of the other SNPs, although the
HR estimates tended to be higher for ER-positive breast
cancer (for example, SNPs rs13387042 at 2q35 and
rs13281615 at 8q24).
Associations with ER status - BRCA2 mutation carriers
Only SNP rs2046210 at 6q25.1 exhibited differential
associations between ER-positive and ER-negative breast
cancer for BRCA2 mutation carriers (P-heterogeneity =
0.045, Table 3). The per-allele HR for ER-negative dis-
ease was estimated to be 1.17 (95% CI: 0.99 to 1.38)
whereas the per-allele HR for ER-positive breast cancer
was 0.97 (95% CI: 0.89 to 1.05). Although there were no
significant differences in the associations between the
two types of disease for BRCA2 mutation carriers, the
HR estimates for ER-positive disease tended to be larger
compared to ER-negative breast cancer. SNPs at/near
FGFR2, TOX3/TNRC9, MAP3K1, LSP1, 2q35, SLC4A7/
NEK10, 5p12 and 1p11.2 were associated with ER-posi-
tive breast cancer for BRCA2 mutation carriers (using
either a per-allele or 2 df genotype test). The strongest
associations were for the FGFR2 rs2981582 SNP (HR for
ER-positive breast cancer = 1.35, 95% CI: 1.23 to 1.48,
P-trend = 1.4 × 10-10) and TOX3/TNRC9 SNP
rs3803662 (HR for ER-positive breast cancer = 1.28.
95% CI: 1.16 to 1.41, P-trend = 1.5 × 10-6). Only SNPs
at or near MAP3K1, STXBP4/COX11 and 6q25.1 were
associated with the risk of ER-negative breast cancer for
BRCA2 mutation carriers.
Associations with PR status - BRCA1 mutation carriers
The general pattern of associations with PR-positive and
PR-negative breast cancer for BRCA1 mutation carriers
(Additional file 1, Table S3) was similar to that seen for
ER status. Significant differences in the associations
between PR-positive and PR-negative breast cancer were
observed for three SNPs. The minor allele of FGFR2
SNP rs2981582 was associated with a significantly
higher risk for PR-positive breast cancer for BRCA1
Mulligan et al. Breast Cancer Research 2011, 13:R110
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Table 2 Genotype and per-allele hazard ratio estimates by estrogen receptor status for BRCA1 mutation carriers
Genotype Unaffected, Affected by subtype, N (%) ER- ER+ P-het
N (%) ER- ER+ Unknown HR 95% CI P-trend HR 95% CI P-trend
FGFR2 rs2981582
GG 1301 (36.2) 447 (40.0) 104 (29.6) 869 (35.1) 1.00 1.00
GA 1,721 (47.9) 516 (46.2) 166 (47.3) 1190 (48.1) 0.93 0.83 to 1.03 1.24 0.98 to 1.57
AA 573 (15.9) 154 (13.8) 81 (23.1) 416 (16.8) 0.82 0.70 to 0.96 1.85 1.40 to 2.44
Per-allele 0.91 0.85 to 0.98 0.01 1.35 1.17 to 1.56 4 × 10-5 6.5 ×10-6
TOX3/TNRC9 rs3803662
CC 1,811 (52.0) 545 (49.5) 154 (45.7) 1195 (50.2) 1.00 1.00
CT 1,405 (40.3) 461 (41.8) 143 (42.4) 987 (41.5) 1.06 0.96 to 1.18 1.20 0.97 to 1.50
TT 269 (7.7) 96 (8.7) 40 (11.9) 199 (8.4) 1.09 0.90 to 1.31 1.61 1.14 to 2.27
Per-allele 1.05 0.97 to 1.13 0.21 1.25 1.06 to 1.46 0.0062 0.07
MAP3K1 rs889312
AA 1,858 (49.6) 569 (49.7) 186 (52.1) 1319 (51.6) 1.00 1.00
AC 1,552 (41.4) 480 (41.9) 136 (38.1) 987 (38.6) 0.97 0.87 to 1.07 0.86 0.69 to 1.06
CC 336 (9.0) 97 (8.5) 35 (9.8) 250 (9.8) 0.97 0.81 to 1.16 0.97 0.69 to 1.35
Per-allele 0.98 0.91 to 1.06 0.56 0.97 0.83 to 1.13 0.69 0.92
LSP1 rs3817198
TT 1,894 (47.4) 652 (45.4) 195 (44.5) 1205 (43.7) 1.00 1.00
TC 1,680 (42.0) 629 (43.8) 197 (45.0) 1239 (44.9) 1.09 0.99 to 1.20 1.11 0.92 to 1.35
CC 422 (10.6) 154 (10.7) 46 (10.5) 315 (11.4) 1.13 0.97 to 1.33 1.10 0.80 to 1.50
Per-allele 1.07 1.00 to 1.15 0.047 1.07 0.93 to 1.22 0.33 0.98
2q35 rs13387042
GG 924 (24.0) 301 (22.1) 93 (22.2) 576 (21.4) 1.00 1.00
GA 1,855 (48.3) 723 (53.1) 194 (46.3) 1370 (50.9) 1.17 1.04 to 1.32 1.02 0.81 to 1.30
AA 1,064 (27.7) 338 (24.8) 132 (31.5) 745 (27.7) 0.96 0.84 to 1.11 1.25 0.97 to 1.62
Per-allele 0.98 0.91 to 1.04 0.48 1.13 0.99 to 1.28 0.075 0.065
8q24 rs13281615
AA 1,319 (32.8) 502 (35.9) 143 (33.7) 897 (32.5) 1.00 1.0
AG 2,008 (50.0) 657 (47.0) 198 (46.7) 1,364 (49.5) 0.98 0.88 to 1.08 0.97 0.79 to 1.19
GG 691 (17.9) 238 (17.0) 83 (19.6) 496 (18.0) 1.00 0.87 to 1.16 1.17 0.89 to 1.53
Per-allele 1.00 0.93 to 1.07 0.93 1.06 0.93 to 1.22 0.38 0.43
SLC4A7/NEK10 rs4973768
CC 1,148 (26.2) 406 (27.2) 103 (22.2) 691 (24.7) 1.00 1.00
CT 2,205 (50.4) 736 (49.3) 235 (50.5) 1,399 (50.1) 0.98 0.88 to 1.08 1.20 0.96 to 1.51
TT 1,024 (23.4) 350 (23.5) 127 (27.3) 703 (25.2) 0.99 0.87 to 1.12 1.38 1.07 to 1.77
Per-allele 0.99 0.93 to 1.06 0.83 1.17 1.03 to 1.33 0.013 0.027
STXBP4/COX11 rs6504950
GG 2,346 (53.1) 814 (53.2) 252 (52.9) 1,502 (53.1)) 1.00 1.00
GA 1,737 (39.3) 593 (37.8) 191 (40.1) 1,127 (39.8) 1.00 0.91 to 1.10 1.03 0.86 to 1.24
AA 333 (7.5) 122 (8.0) 33 (6.9) 200 (7.1) 1.04 0.88 to 1.23 0.94 0.65 to 1.34
Per-allele 1.01 0.94 to 1.09 0.77 1.00 0.87 to 1.15 0.97 0.87
5p12 rs10941679
AA 2,211 (55.8) 815 (57.3) 271 (61.0) 1,529 (56.5) 1.00 1.00
AG 1,472 (37.1) 517 (36.4) 145 (32.7) 1,001 (37.0) 0.99 0.90 to 1.09 0.84 0.69 to 1.02
GG 280 (7.1) 90 (6.3) 28 (6.3) 177 (6.5) 0.89 0.73 to 1.08 0.84 0.58 to 1.20
Per-allele 0.97 0.90 to 1.04 0.39 0.88 0.75 to 1.02 0.08 0.26
6q25.1 - rs2046210
CC 1,886 (43.3) 567 (38.2) 158 (36.0) 1,007 (37.0) 1.00 1.00
TC 1,919 (44.1) 718 (48.3) 232 (52.9) 1,305 (48.0) 1.21 1.10 to 1.33 1.37 1.13 to 1.67
TT 547 (12.6) 201 (13.5) 49 (11.2) 409 (15.0) 1.39 1.21 to 1.59 1.11 0.81 to 1.53
Per-allele 1.19 1.11 to 1.27 2.4 × 10-7 1.14 1.01 to 1.30 0.043 0.60
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mutation carriers (per-allele HR for PR-positive = 1.29,
95% CI: 1.10 to 1.51, HR for PR-negative = 0.93, 95%
CI: 0.87 to 1.00, P-heterogeneity = 7 × 10-4). Allele “A”
of SNP rs13387042 at 2q35 was associated with a signif-
icantly higher risk of PR-positive breast cancer for
BRCA1 mutation carriers (HR for PR-positive breast
cancer = 1.16, 95% CI: 1.01 to 1.33; HR for PR-negative
= 0.97, 95% CI: 0.91 to 1.04, P-heterogeneity = 0.034).
Although the RAD51L1 SNP showed no differential
associations with ER-status, there was evidence that the
minor allele of this SNP was associated with a lower
risk of PR-positive breast cancer (HR for PR-positive =
0.79, 95% CI: 0.61 to 0.95; HR for PR-negative = 1.02,
95% CI: 0.94 to 1.11; P-heterogeneity = 0.027). The only
SNPs associated with risk for PR-negative breast cancer
were SNPs at 6q25.1 (per-allele HR = 1.19, 95% CI: 1.11
to 1.27, P-trend = 3.7 × 10-7), and in LSP1 (per-allele
HR = 1.09, 95% CI: 1.01 to 1.16, P-trend = 0.017), but
these were not significantly different from the associa-
tions with PR-positive breast cancer for BRCA1 muta-
tion carriers.
Associations with PR status - BRCA2 mutation carriers
Only two SNPs demonstrated significant differences in
the associations with PR-positive and PR-negative breast
cancer for BRCA2 mutation carriers (Additional file 1,
Table S4). SNP rs13387042 at 2q35 was associated with
a higher risk of PR-positive breast cancer (per-allele HR
for PR-positive = 1.14, 95% CI: 1.03 to 1.25; per-allele
HR for PR-negative = 0.92, 95% CI: 0.81 to 1.04, P-het-
erogeneity = 0.009). SNP rs10941679 at 5p12 was also
associated with a higher risk of PR-positive breast can-
cer for BRCA2 mutation carriers (per-allele HR for PR-
positive = 1.15. 95% CI: 1.03 to 1.27, HR for PR-negative
= 0.94, 95% CI: 0.81 to 1.09, P-heterogeneity = 0.028).
SNPs near or at FGFR2, TOX3/TNRC9, LSP1 were asso-
ciated with both PR-negative and PR-positive breast
cancer, whereas the 1p11.2 SNP was associated with risk
for PR-negative breast cancer. MAP3K1 and SLC4A7/
NEK10 were associated only with risk of PR-positive
breast cancer among BRCA2 mutation carriers.
Absolute risks of developing ER-positive and ER-negative
breast cancer by SNP profile
Using the estimated HRs for ER-positive and ER-nega-
tive breast cancer for BRCA1 and BRCA2 mutation car-
riers, we computed the predicted absolute risk of
developing ER-negative and ER-positive breast cancer at
various percentiles of the combined SNP distribution.
The SNP profile distribution is different for each disease
subtype and mutation. We note that SNPs for which the
per-allele HR estimates are close to 1.0 contribute little
to the predicted ER-specific risks. Figure 1 shows the
predicted risks of developing ER-negative and ER-posi-
tive breast cancer for BRCA1 and BRCA2 mutation car-
riers at the 5th, 50th and 95th percentiles of the empirical
risk distribution of the combined SNP profile. A BRCA1
mutation carrier at the 5th percentile of the SNP profile
distribution would be at 43% risk of developing ER-
negative breast cancer by age 80 compared with 60% for
BRCA1 mutation carriers at the 95th percentile of the
risk distribution. The risks of developing ER-positive
breast cancer would be 18% and 46% by age 80 at the
5th and 95th percentiles of the ER-positive breast cancer
risk distribution. BRCA2 mutation carriers at the 5th
percentile of the ER-negative breast cancer risk distribu-
tion are predicted to have a 22% risk of developing ER-
negative breast cancer by age 80 compared with 39% for
the 95th percentile of the risk distribution. The risks of
developing ER-positive breast cancer by age 80 for
BRCA2 carriers varied from 33% to 70% at the 5th and
95th percentiles of the ER-positive risk distribution
respectively.
Discussion
This is the first report to investigate the associations
between 12 common breast cancer susceptibility alleles
and ER and PR status of breast tumours in BRCA1 and
Table 2 Genotype and per-allele hazard ratio estimates by estrogen receptor status for BRCA1 mutation carriers
(Continued)
1p11.2 - rs11249433
TT 1,491 (34.1) 506 (33.7) 144 (32.4) 973 (35.1) 1.00 1.00
CT 2,133 (48.7) 745 (49.7) 245 (55.2) 1,342 (48.5) 0.97 0.88 to 1.07 1.10 0.90 to 1.34
CC 752 (17.2) 248 (16.5) 55 (12.4) 455 (16.4) 0.99 0.87 to 1.13 0.76 0.56 to 1.03
Per-allele 0.99 0.93 to 1.06 0.79 0.92 0.81 to 1.05 0.22 0.35
RAD51L1 - rs999737/rs10483813
CC/TT 2,335 (61.5) 760 (64.1) 212 (62.5) 1,551 (62.5) 1.00 1.00
TC/AT 1,294 (34.1) 370 (31.2) 113 (33.3) 819 (33.0) 0.92 0.83 to 1.03 1.00 0.80 to 1.24
TT/AA 170 (4.5) 56 (4.7) 14 (4.1) 110 (4.4) 1.02 0.81 to 1.28 0.93 0.56 to 1.56
per allele 0.96 0.88 to 1.04 0.34 0.98 0.82 to 1.18 0.87 0.81
P-het, Heterogeneity P-value; ER-, estrogen receptor negative; ER+, estrogen receptor positive
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Table 3 Genotype and per-allele hazard ratio estimates by estrogen receptor status for BRCA2 mutation carriers
Genotype Unaffected, Affected by subtype, N (%) ER- ER+ P-het
N (%) ER- ER+ Unknown HR 95%CI P-
trend
HR 95% CI P-trend
FGFR2 rs2981582
GG 794 (37.8) 86 (32.7) 248
(29.5)
457 (29.8) 1.00 1.00
GA 987 (47.0) 137 (52.1) 419
(49.8)
755 (49.3) 1.28 0.99 to 1.67 1.35 1.17 to 1.55
AA 321 (15.3) 40 (15.2) 174
(20.7)
320 (20.9) 1.23 0.85 to 1.78 1.81 1.51 to 2.18
Per-allele 1.14 0.97 to 1.35 0.12 1.35 1.23 to 1.48 1.4 × 10-10 0.097
TOX3/TNRC9 rs3803662
CC 1,088 (53.4) 136 (53.3) 377
(46.3)
702 (48.2) 1.00 1.00
CT 792 (38.9) 96 (37.7) 361
(44.3)
604 (41.5) 0.98 0.75 to 1.27 1.33 1.17 to 1.53
TT 157 (7.7) 23 (9.0) 77 (9.5) 150 (10.3) 1.27 0.83 to 1.93 1.54 1.22 to 1.95
Per-allele 1.06 0.88 to 1.29 0.53 1.28 1.16 to 1.41 1.5 × 10-6 0.11
MAP3K1 rs889312
AA 1,107 (51.1) 121 (45.7) 430
(50.3)
746 (47.7) 1.00 1.00
AC 888 (41.0) 120 (45.3) 349
(40.8)
646 (41.3) 1.23 0.96 to 1.59 1.03 0.90 to 1.17
CC 170 (7.9) 24 (9.1) 76 (8.9) 172 (11.0) 1.42 0.93 to 2.16 1.29 1.03 to 1.62
Per-allele 1.21 1.01 to 1.45 0.039 1.09 0.99 to 1.21 0.08 0.35
LSP1 rs3817198
TT 1,075 (46.1) 142 (44.4) 429
(42.0)
718 (42.7) 1.00 1.00
TC 1,005 (43.1) 146 (45.6) 466
(45.6)
759 (45.2) 1.08 0.86 to 1.36 1.14 1.01 to 1.29
CC 252 (10.8) 32 (10.0) 127
(12.4)
203 (12.1) 1.02 0.68 to 1.51 1.39 1.14 to 1.70
Per-allele 1.03 0.87 to 1.22 0.70 1.17 1.07 to 1.28 5.5 × 10-4 0.20
2q35 rs13387042
GG 571 (25.3) 71 (23.0) 216
(22.0)
382 (23.1) 1.00 1.00
GA 1,080 (47.8) 156 (50.5) 500
(50.8)
809 (48.8) 1.12 0.85 to 1.47 1.18 1.01 to 1.36
AA 608 (26.9) 82 (26.5) 268
(27.2)
466 (28.1) 1.06 0.78 to 1.45 1.13 0.95 to 1.34
Per-allele 1.03 0.87 to 1.19 0.71 1.06 0.97 to 1.15 0.20 0.75
8q24 rs13281615
AA 794 (34.1) 99 (31.6) 317
(31.7)
524 (31.3) 1.00 1.00
AG 1,156 (49.6) 165 (52.7) 511
(51.1)
837 (49.9) 1.08 0.85 to 1.38 1.05 0.92 to 1.21
GG 382 (16.4) 49 (15.7) 172
(17.2)
315 (18.8) 1.05 0.75 to 1.46 1.13 0.94 to 1.35
Per-allele 1.04 0.89 to 1.21 0.66 1.06 0.97 to 1.16 0.19 0.80
SLC4A7/NEK10 rs4973768
CC 669 (26.5) 82 (24.9) 251
(22.6)
401 (23.5) 1.00 1.00
CT 1,241 (49.1) 164 (49.9) 546
(49.4)
829 (48.7) 1.05 0.81 to 1.36 1.14 0.99 to 1.31
TT 618 (24.5) 83 (25.2) 311
(28.0)
474 (27.8) 1.04 0.77 to 1.41 1.27 1.08 to 1.50
Per-allele 1.02 0.88 to 1.19 0.78 1.13 1.04 to 1.22 0.0043 0.25
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BRCA2 mutation carriers. The analysis was made possi-
ble by the availability of a large, combined dataset with
genotype and tumour pathology information in muta-
tion carriers collated through the CIMBA consortium.
The majority of the SNPs examined demonstrated
stronger associations with ER-positive breast cancer for
both BRCA1 and BRCA2 mutation carriers (Figure 2).
Only rs2046210 on 6q25.1 exhibited stronger evidence
for ER-negative disease. Among BRCA1 mutation car-
riers, the most marked difference was for SNP
rs2981582 in FGFR2, which was strongly associated with
ER-positive breast cancer and exhibited no evidence of
an association with ER-negative breast cancer (P = 6.5 ×
10-6). Previous analyses of this polymorphism in
mutation carriers failed to find an association with the
overall risk of breast cancer for BRCA1 mutation car-
riers, but found an association with risk for BRCA2
mutation carriers [29,31]. Our results suggest that
rs2981582 in FGFR2 also modifies ER-positive breast
cancer risk for BRCA1 mutation carriers to a similar
relative extent as in BRCA2 mutation carriers and ER-
positive disease in the general population [27,32]. Simi-
lar patterns were observed for SNPs rs3803662 in
TOX3/TNRC9 and rs4973768 in SLC4A7/NEK10 in
which the associations were predominantly with ER-
positive breast cancer for both BRCA1 and BRCA2
mutation carriers, in line with results from studies of
breast cancer in the general population [18,21,27]. The
Table 3 Genotype and per-allele hazard ratio estimates by estrogen receptor status for BRCA2 mutation carriers
(Continued)
STXBP4/COX11 rs6504950
GG 1,420 (55.6) 171 (51.0) 601
(53.1)
896 (52.5) 1.00 1.00
GA 951 (37.2) 145 (43.3) 444
(39.3)
684 (40.1) 1.27 1.03 to 1.58 1.09 0.97 to 1.23
AA 184 (7.2) 19 (5.7) 86 (7.6) 127 (7.4) 0.84 0.54 to 1.30 1.08 0.87 to 1.34
Per-allele 1.07 0.92 to 1.25 0.36 1.06 0.97 to 1.16 0.19 0.91
5p12 rs10941679
AA 1,372 (58.6) 176 (54.8) 584
(54.8)
924 (56.3) 1.00 1.00
AG 824 (35.2) 122 (38.0) 425
(39.9)
622 (37.9) 1.08 0.86 to 1.37 1.15 1.01 to 1.30
GG 146 (6.2) 23 (7.2) 57 (5.4) 94 (5.7) 1.25 0.82 to 1.91 0.94 0.73 to 1.22
Per-allele 1.10 0.92 to 1.31 0.28 1.06 0.96 to 1.17 0.23 0.70
6q25.1 - rs2046210
CC 985 (39.8) 121 (39.2) 466
(42.1)
634 (37.7) 1.00 1.00
TC 1,165 (47.1) 132 (42.7) 499
(45.1)
802 (47.7) 0.99 0.78 to 1.12 0.96 0.85 to 1.08
TT 324 (13.1) 56 (18.1) 141
(12.8)
247 (14.7) 1.47 1.08 to 2.01 0.94 0.78 to 1.12
Per-allele 1.17 0.99 to 1.38 0.059 0.97 0.89 to 1.05 0.41 0.045
1p11.2 -
rs11249433
TT 895 (35.9) 107 (33.6) 345
(31.4)
599 (34.7) 1.00 1.00
CT 1,226 (49.2) 160 (50.3) 553
(50.3)
843 (48.9) 1.00 0.79 to 1.28 1.08 0.96 to 1.23
CC 371 (14.9) 51 (16.0) 202
(18.4)
282 (16.4) 1.00 0.73 to 1.40 1.27 1.08 to 1.50
Per-allele 1.00 0.86 to 1.17 0.98 1.12 1.03 to 1.22 0.0065 0.23
RAD51L1 - rs999737/
rs10483813
BRCA1 CC/TT 1,368
(59.5)
167
(59.0)
589 (61.4) 1,000
(62.0)
1.00 1.00
TC/AT 789 (34.3) 104 (36.8) 323
(33.6)
534 (33.1) 1.06 0.84 to 1.35 0.94 0.83 to 1.07
TT/AA 141 (6.1) 12 (4.2) 48 (5.0) 80 (4.9) 0.74 0.42 to 1.32 0.87 0.67 to 1.14
Per-allele 0.97 0.80 to 1.17 0.73 0.94 0.85 to 1.03 0.20 0.77
P-het, Heterogeneity P-value; ER-, estrogen receptor negative; ER+, estrogen receptor positive
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HR estimates for ER-positive breast cancer in BRCA1
and BRCA2 mutation carriers for these SNPs were very
similar.
Among the 12 SNPs investigated in this report, SNP
rs2046210 at 6q25.1 exhibited the strongest association
with the risk of breast cancer for BRCA1 mutation car-
riers in previous analyses, and was not associated with
risk for BRCA2 mutation carriers [28]. The current
results suggest that this was mainly driven by an
association with ER-negative breast cancer risk. This
observation is again consistent with the effects seen in
population-based studies, in which the relative risk is
higher for ER-negative than ER-positive disease [42,43]
(Alison Dunning, personal communication). There was
some evidence that the 6q25.1 SNP is also associated
with ER-negative disease cancer subtype in BRCA2
mutation carriers, although the estimates for ER-nega-
tive breast cancer in BRCA2 mutation carriers are
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Figure 1 Predicted risks of developing ER-negative and ER-positive breast cancer based on SNP profiles. Solid lines depict the median
risks and dotted lines the risks at the 5th and 95th percentiles of the risk distribution. The absolute risk differences between individuals at the
extremes of the risk distributions are greater for ER-positive breast cancer.
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imprecise due to the relatively small sample size. In
addition to the 12 loci investigated in this report, a
recently identified locus at 19p13 also appears to be pre-
dominantly associated with ER-negative breast cancer
[44].
The patterns of association between the SNPs and PR
tumour status were similar to those observed for ER,
which is not surprising given that ER and PR expression
are highly correlated. There were, however, two notable
exceptions. The 2q35 SNP rs13387042 demonstrated
significantly stronger associations with PR-positive than
PR-negative breast cancer for both BRCA1 and BRCA2
mutation carriers (P = 0.034 and P = 0.0086, for PR-
positive for BRCA1 and BRCA2 respectively), suggesting
this SNP may be more relevant for BRCA1 and BRCA2
tumours expressing PR. However, a population-based
study has found this SNP is also associated with PR-
negative breast cancer [45]. Furthermore, the RAD51L1
locus was associated with PR-positive breast cancer for
BRCA1 mutation carriers and the magnitude of the
association was similar to that observed in the general
population [23] (A.B. Spurdle, personal communication).
Previous studies demonstrated that SNPs, which are
associated with ER-positive breast cancer in the general
population, tend to be associated with the breast cancer
risk for BRCA2 mutation carriers and SNPs, which are
associated with ER-negative breast cancer in the general
population, tend to be associated with the breast cancer
Figure 2 Summary of per-allele HR estimates for ER-positive and ER-negative breast cancer for mutation carriers. The patterns of per-
allele HR estimates (taken from Tables 2 and 3) suggest that the breast cancer subtype specific associations are similar between BRCA1 and
BRCA2 mutation carriers.
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risk for BRCA1 mutation carriers [27,31,44-46]. The
current results demonstrate that despite lack of an asso-
ciation between a SNP and the overall breast cancer risk
for BRCA1 or BRCA2 mutation carriers, residual asso-
ciations exist with specific disease subtypes. Figure 2
summarises the association patterns in BRCA1 and
BRCA2 mutation carriers. The HR estimates for ER-
positive and ER-negative breast cancer among BRCA1
mutation carriers appear to be different (intraclass cor-
relation coefficient (ICC) approximately 0), as are the
HR estimates for ER-positive and ER-negative breast
cancer among BRCA2 mutation carriers (ICC = 0.13).
On the other hand the HR estimates for ER-positive
breast cancer among BRCA1 and BRCA2 mutation car-
riers appear to be more similar (ICC = 0.65). There is,
however, little correlation in the HR estimates for ER-
negative breast cancer among BRCA1 and BRCA2 muta-
tion carriers (ICC = 0.05). However, SNP 6q25.1, which
is mainly associated with ER-negative disease in BRCA1
mutation carriers, is estimated to confer similar HRs for
ER-negative breast cancer for both BRCA1 and BRCA2
mutation carriers. These associations are mainly in the
same direction and of similar magnitude to those
observed with breast cancer in the general population
stratified by ER expression status. Taken together, these
findings are consistent with a model in which these
SNPs and BRCA1 or BRCA2 mutations combine multi-
plicatively on the risk for ER-positive or ER-negative
breast cancer [47]. Hence, the apparent differences in
the strength of the SNP associations by BRCA1 and
BRCA2 mutation status can be explained once tumour
subtype is taken into account.
The major strength of the current study is the large
sample of BRCA1 and BRCA2 mutation carriers with
SNP and tumour marker information. Despite the large
sample size, ER and PR marker information was only
available for approximately 30% of the mutation carriers
that had been diagnosed with breast cancer. The sample
sizes for tumour subtypes, while still large, were, there-
fore, much smaller than were available for analyses of
breast cancer risk overall, particularly for ER-positive
breast cancer in BRCA1 carriers and ER-negative breast
cancer in BRCA2 carriers. However, by analysing the data
using a retrospective cohort approach and analysing the
associations with ER-positive and ER-negative disease
simultaneously we were able to include all mutation car-
riers in the analysis, including affected individuals with
missing ER status, thus maximizing the available infor-
mation. Ongoing efforts by CIMBA aim to increase the
proportion of mutation carriers diagnosed with breast
cancer who also have available tumour pathology infor-
mation. This will enable us to assess the associations
with breast cancer subtypes with greater precision.
The majority of the mutation carriers in CIMBA are
identified through clinical genetics centers and, there-
fore, the source of information or definition of tumour
marker status could vary across studies. This heteroge-
neity in classification may attenuate some of the differ-
ences by tumour type. For example, most commonly, a
cut-off of 10% of cells staining was taken to denote posi-
tivity for ER and PR by the centers without further
information on intensity or proportion of positive
tumour nuclei and this was used for all our analyses;
however, in centers that use the Allred score, a value of
> 2 denoted positivity, which may reflect as few as 1%
of cells staining. In fact, recent recommendations sug-
gest that ER and PgR assays be considered positive, for
therapeutic purposes, if there are at least 1% positive
tumour nuclei [48], but these data were not available for
the majority of carriers in our samples to enable reclas-
sification. It has been shown, however, that ER is almost
always diffusely positive or completely negative (that is,
it shows a bimodal staining pattern) with few cases fall-
ing between these extremes [49]. Given the small num-
ber of tumours likely to fall into the1 to 9% of cells
staining category, the impact of changing the cutoff to
1% on our results would be limited. Furthermore, there
was no evidence of variation in the distributions of ER
or PR status across the studies separately for BRCA1
and BRCA2 tumours (Mavaddat N, Antoniou AC, per-
sonal communication, manuscript in preparation) and
all analyses were stratified by country. Finally, the clear
differences observed for some SNPs (most notably for
FGFR2 rs2981582, where the association was limited to
ER-positive disease) suggest that the effect of misclassifi-
cation in tumour subtype on the SNP associations is
likely to have been small.
BRCA1 and BRCA2 tumours have also been found to
differ in terms of other tumour characteristics compared
to breast cancers in the general population. For exam-
ple, tumours in mutation carriers are more likely to be
of higher grade in comparison to breast cancers in the
general population. The distribution of grade has been
found to vary between ER-positive and ER-negative
tumours in both BRCA1 and BRCA2 mutation carriers
(Mavaddat N, Antoniou AC, personal communication,
manuscript in preparation). Although the number of
carriers with information on grade, ER status and SNPs
was too small to permit combined analysis, our results
are unlikely to have been influenced after adjusting for
tumour grade. Case-only analysis to test for differences
in associations between the SNPs and tumour grade
(using ordinal logistic regression) revealed no significant
associations between any of the SNPs and grade for
both BRCA1 and BRCA2 mutation carriers (P > 0.05 for
all tests, results not shown).
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The analysis was performed within a retrospective
cohort approach, by extending the retrospective likeli-
hood approach described previously [36] to model the
simultaneous effects on different breast cancer subtypes
defined by ER/PR. Under this approach the associations
were estimated simultaneously for the tumour subtypes
under investigation. This method depends on the
assumption that ascertainment of mutation carriers does
not depend on tumour subtypes. This is a reasonable
assumption since more than 90% of mutation carriers in
our sample were recruited prior to 2007, when it was
uncommon to use tumour pathology in selecting indivi-
duals for BRCA1 and BRCA2 mutation screening.
Furthermore, the results were virtually identical in a
case only, logistic regression analysis for testing for dif-
ferences in the associations with tumour subtypes which
included only individuals with known tumour character-
istics (results not shown).
The average risks of developing ER-positive and ER-
negative breast cancer in both BRCA1 and BRCA2
mutation carriers are substantially higher compared to
the general population [38]. Therefore, in combination,
these SNPs lead to much bigger differences in the
absolute risk of developing the disease subtypes
between the extremes of the combined SNP genotype
distributions [50]. Based on the SNP profiles investi-
gated in this report, the absolute risk difference
between mutation carriers at the top 5% of the risk
distribution compared to the bottom 5% is much
greater for ER-positive breast cancer than for ER-nega-
tive breast cancer for both BRCA1 and BRCA2 (Figure
1). Recent GWAS have identified several other com-
mon breast cancer susceptibility variants which have
not been investigated in BRCA1 and BRCA2 mutation
carriers yet [24,51]. Moreover, ongoing GWAS in
BRCA1 and BRCA2 mutation carriers [44,52] may also
identify further modifiers of breast cancer risk for
mutation carriers. It will be important to investigate
the associations of these variants with different disease
subtypes in BRCA1 and BRCA2 mutation carriers. Cur-
rently, it is unusual for the risks of different disease
subtypes to be taken into account in the genetic coun-
seling process. However, as more risk modifying var-
iants are identified in the future, provided these have
different associations with different disease subtypes in
mutation carriers and confer relative risks which are
greater (or smaller) than 1, having precise breast can-
cer subtype risks may be useful for the planning of the
clinical management of both BRCA1 and BRCA2 muta-
tion carriers. For example, knowing that a female
BRCA1 mutation carrier was primarily at risk of ER-
positive breast cancer based on her associated SNP
profile (rather than ER-negative breast cancer, as is the
case for the majority of cases) might potentially
influence the choice of clinical management by screen-
ing, chemoprevention or prophylactic surgery.
Conclusions
In summary, in this report we investigated the associa-
tions of common breast cancer polymorphisms with ER
and PR status. Our results indicate there are differential
associations between these SNPs and the risk of devel-
oping ER-positive or ER-negative breast cancer in
BRCA1 and BRCA2 mutation carriers that mirror simi-
lar differences seen in the general population. The find-
ings add to our understanding of the biology of tumour
development in mutation carriers and as more risk var-
iants are identified in the future they may improve clini-
cal management of these individuals.
Additional material
Additional file 1: Supplementary Tables. Supplementary Table 1: List
of local ethics committees that approved studies. Supplementary Table 2:
Methods and thresholds used to define the final marker variables.
Supplementary Table 3: Per-allele hazard ratio estimates by progesterone
receptor status for BRCA1 mutation carriers. Supplementary Table 4: Per-
allele hazard ratio estimates by progesterone receptor status for BRCA2
mutation carriers.
Abbreviations
CIMBA: Consortium of Investigators of Modifiers of BRCA1/2; ER: estrogen
receptor; GWAS: genome-wide association studies; HR: hazard ratio; PR:
progesterone receptor; SNPs: single nucleotide polymorphisms.
Acknowledgements
This work was supported by Cancer Research UK grants C12292/A11174 and
C1287/A10118. The research leading to these results has received funding
from the European Community’s Seventh Framework Programme under
grant agreement n° 223175 (HEALTH-F2-2009-223175). ACA is a CR-UK
Senior Cancer Research Fellow, DFE is CR-UK Principal Research Fellow.
Study specific acknowledgments
Breast Cancer Family Registry (BCFR)
This work was supported by the National Cancer Institute, National Institutes
of Health under RFA-CA-06-503 and through cooperative agreements with
members of the Breast Cancer Family Registry (BCFR) and Principal
Investigators, including Cancer Care Ontario (U01 CA69467), Columbia
University (U01 CA69398), Fox Chase Cancer Center (U01 CA69631),
Huntsman Cancer Institute (U01 CA69446), Cancer Prevention Institute of
California (formerly the Northern California Cancer Center) (U01 CA69417),
University of Melbourne (U01 CA69638), and Research Triangle Institute
Informatics Support Center (RFP No. N02PC45022-46). Samples from the
FCCC, HCI, and CPIC were processed and distributed by the Coriell institute
for Medical Research. The content of this manuscript does not necessarily
reflect the views or policies of the National Cancer Institute or any of the
collaborating centers in the BCFR, nor does mention of trade names,
commercial products or organizations imply endorsement by the US
Government or the BCFR.
The Baltic Familial Breast and Ovarian Cancer Consortium (BFBOCC Latvia
and Lithuania)
Lithuania: This work is supported by the Research Council of Lithuania grant
LIG-19/2010 to Ramunas Janavicius. Latvia: We acknowledge Genome
Database of Latvian Population, Latvian Biomedical Research and Study
Center for providing data and DNA samples. This work is supported by
Liepaja’s municipal council to Laima Tihomirova (Latvian Biomedical
Research and Study Centre).
Copenhagen Breast Cancer Study (CBCS)
Mulligan et al. Breast Cancer Research 2011, 13:R110
http://breast-cancer-research.com/content/13/6/R110
Page 14 of 20
We thank the NEYE Foundation for financial support
The Deutsches Krebsforschungszentrum (DKFZ) study
The study was supported by the DKFZ.
The CONSIT TEAM is supported by grants from Associazione Italiana per la
Ricerca sul Cancro (4017) and by funds from Italian citizens who allocated
the 5 × 1,000 share of their tax payment in support of the Fondazione
IRCCS Istituto Nazionale Tumouri, according to Italian laws (INT-Institutional
strategic projects “5 × 1000”) to PP and grants from Fondazione Italiana per
la Ricerca sul Cancro (Special Project “Hereditary tumours”), Ministero della
Salute (Extraordinary National Cancer Program 2006 “Alleanza contro il
Cancro”, and “Progetto Tumouri Femminili”) and Ministero dell’Universita’ e
Ricerca (RBLAO3-BETH) to PR. CONSIT TEAM acknowledges the contribution
of Gaia Roversi, Carla B. Ripamonti, Marilena Morganti and Marco Pierotti of
the of the Fondazione IRCCS Istituto Nazionale dei Tumouri, Milan, Italy;
Monica Barile of the Istituto Europeo di Oncologia, Milan, Italy and Liliana
Varesco of the Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.
Epidemiological study of BRCA1 and BRCA2 mutation carriers (EMBRACE)
EMBRACE Collaborating Centers are: Coordinating Centre, Cambridge: Steve
Ellis, Elena Fineberg, Radka Platte. North of Scotland Regional Genetics
Service, Aberdeen: Zosia Miedzybrodzka. Northern Ireland Regional Genetics
Service, Belfast: Patrick Morrison, Lisa Jeffers. West Midlands Regional Clinical
Genetics Service, Birmingham: Trevor Cole, Kai-ren Ong, Jonathan Hoffman.
South West Regional Genetics Service, Bristol: Margaret James. East Anglian
Regional Genetics Service, Cambridge: Joan Paterson, Sarah Downing, Amy
Taylor. Medical Genetics Services for Wales, Cardiff: T. Rogers,. St James’s
Hospital, Dublin & National Centre for Medical Genetics, Dublin: M. John
Kennedy, David Barton. South East of Scotland Regional Genetics Service,
Edinburgh: Mary Porteous, Sarah Drummond. Peninsula Clinical Genetics
Service, Exeter: Carole Brewer, Emma Kivuva, Anne Searle, Selina Goodman,
Kathryn Hill. West of Scotland Regional Genetics Service, Glasgow: Victoria
Murday, Nicola Bradshaw, Lesley Snadden, Mark Longmuir, Catherine Watt,
Sarah Gibson, Eshika Haque, Ed Tobias, Alexis Duncan. South East Thames
Regional Genetics Service, Guy’s Hospital London: Chris Jacobs, Caroline
Langman, Anna Whaite. North West Thames Regional Genetics Service,
Harrow. Leicestershire Clinical Genetics Service, Leicester. Yorkshire Regional
Genetics Service, Leeds: Carol Chu, Julie Miller. Cheshire and Merseyside
Clinical Genetics Service, Liverpool: Ian Ellis. Manchester Regional Genetics
Service, Manchester: Jane Taylor. North East Thames Regional Genetics
Service, NE Thames, London: Alison Male, Cheryl Berlin. Nottingham Centre
for Medical Genetics, Nottingham: Rebecca Collier. Northern Clinical Genetics
Service, Newcastle: Fiona Douglas, Oonagh Claber, Irene Jobson. Oxford
Regional Genetics Service, Oxford: Lisa Walker, Diane McLeod, Dorothy
Halliday, Sarah Durell, Barbara Stayner. The Institute of Cancer Research and
Royal Marsden NHS Foundation Trust: Susan Shanley, Nazneen Rahman,
Richard Houlston, Elizabeth Bancroft, Lucia D’Mello, Elizabeth Page, Audrey
Ardern-Jones, Kelly Kohut, Jennifer Wiggins, Elena Castro, Anita Mitra, Lisa
Robertson. North Trent Clinical Genetics Service, Sheffield: Oliver Quarrell,
Cathryn Bardsley. South West Thames Regional Genetics Service, London:
Shirley Hodgson, Sheila Goff, Glen Brice, Lizzie Winchester, Charlotte Eddy,
Vishakha Tripathi, Virginia Attard. Wessex Clinical Genetics Service, Princess
Anne Hospital, Southampton: Anneke Lucassen, Gillian Crawford, Donna
McBride, Sarah Smalley. EMBRACE is supported by Cancer Research UK
Grants C1287/A10118 and C1287/A11990. D. Gareth Evans and Fiona Lalloo
are supported by an NIHR grant to the Biomedical Research Centre,
Manchester. The Investigators at The Institute of Cancer Research and The
Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the
Biomedical Research Centre at The Institute of Cancer Research and The
Royal Marsden NHS Foundation Trust. Ros Eeles, Elizabeth Bancroft and Lucia
D’Mello are also supported by Cancer Research UK Grant C5047/A8385.
Fox Chase Cancer Center Study (FCCC)
Fox Chase Cancer Center Biosample Repository: We acknowledge M. Pat
Gilroy, Lesley Cruz, Diane Faison, Barbara Dettore, Mary Donovan, and
Meghan Butler for their help collecting patient data and samples. University
of Kansas Medical Center (KUMC):
A.K.G. was funded by U01CA69631, 5U01CA113916, and the Eileen Stein
Jacoby Fund. The author acknowledges support from The University of
Kansas Cancer Center and the Kansas Bioscience Authority Eminent Scholar
Program. A.K.G. is the Chancellors Distinguished Chair in Biomedical Sciences
endowed Professor.
Georgetown University
Work is supported by the Familial Cancer Registry (CI) and the Tissue Culture
Shared Registry at Georgetown University (NIH/NCI grant P30-CA051008), the
Cancer Genetics Network (HHSN261200744000C) (CI), and Swing Fore the
Cure (CI).
The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC)
GC-HBOC is supported by a grant of the German Cancer Aid (grant 109076),
the Centre of Molecular Medicine Cologne (CMMC).
Genetic Modifiers of cancer risk in BRCA1/2 mutation carriers (GEMO) study:
Cancer Genetics Network “Groupe Génétique et Cancer”, Fédération
Nationale des Centres de Lutte Contre le Cancer, France
The study was supported by the Ligue National Contre le Cancer;
Association for International Cancer Research Grant (AICR-07-0454); and the
Association “Le cancer du sein, parlons-en!” Award. We wish to thank all the
GEMO collaborating groups for their contribution to this study. GEMO
Collaborating Centers are: Coordinating Centres, Unité Mixte de Génétique
Constitutionnelle des Cancers Fréquents, Centre Hospitalier Universitaire de
Lyon/Centre Léon Bérard, et Equipe «Génétique du cancer du sein», Centre
de Recherche en Cancérologie de Lyon: Laure Barjhoux, Carole Verny-Pierre,
Sophie Giraud, and Service de Génétique Oncologique, Institut Curie, Paris:
Marion Gauthier-Villars, Bruno Buecher, Claude Houdayer, Muriel Belotti,
Carole Tirapo, Antoine de Pauw. Institut Gustave Roussy, Villejuif: Brigitte
Bressac-de-Paillerets, Audrey Remenieras, Véronique Byrde, Olivier Caron,
Gilbert Lenoir. Centre Jean Perrin, Clermont-Ferrand: Yves-Jean Bignon,
Nancy Uhrhammer. Centre Léon Bérard, Lyon: Christine Lasset, Valérie
Bonadona. Centre François Baclesse, Caen. Institut Paoli Calmettes, Marseille:
Hagay Sobol, Violaine Bourdon, Tetsuro Noguchi, François Eisinger. Groupe
Hospitalier Pitié-Salpétrière, Paris: Florence Coulet, Chrystelle Colas, Florent
Soubrier. CHU de Arnaud-de-Villeneuve, Montpellier. Centre Oscar Lambret,
Lille: Jean-Philippe Peyrat, Joëlle Fournier, Françoise Révillion, Philippe
Vennin, Claude Adenis. Hôpital René Huguenin/Institut Curie, St Cloud:
Etienne Rouleau, Rosette Lidereau, Liliane Demange, Catherine Nogues.
Centre Paul Strauss, Strasbourg. Institut Bergonié, Bordeaux: Emmanuelle
Barouk-Simonet, Françoise Bonnet, Virginie Bubien. Institut Claudius Regaud,
Toulouse: Christine Toulas, Rosine Guimbaud, Laurence Gladieff, Viviane
Feillel. CHU de Grenoble: Dominique Leroux, Hélène Dreyfus, Christine
Rebischung, Magalie Peysselon. CHU de Dijon: Fanny Coron, Laurence Faivre.
CHU de St-Etienne: Fabienne Prieur. Hôtel Dieu Centre Hospitalier,
Chambéry: Sandra Fert Ferrer. Centre Antoine Lacassagne, Nice: Marc Frénay.
CHU de Limoges: Laurence Vénat-Bouvet. CHU de Nantes: Capucine
Delnatte. CHU Bretonneau, Tours. Creighton University, Omaha, USA: Henry
T.Lynch, Carrie L.Snyder.
The Hereditary Breast and Ovarian Cancer Research Group Netherlands
(HEBON)
HEBON Collaborating Centers: Coordinating center: Netherlands Cancer
Institute, Amsterdam, NL: FBL Hogervorst, S Verhoef, M Verheus, LJ van ‘t
Veer, FE van Leeuwen; Erasmus Medical Center, Rotterdam, NL: M Collée,
AMW van den Ouweland, A Jager, MJ Hooning; Leiden University Medical
Center, NL, Leiden: CJ van Asperen, JT Wijnen, MP Vreeswijk, RA Tollenaar, P
Devilee; Radboud University Nijmegen Medical Center, Nijmegen, NL: MJ
Ligtenberg, N Hoogerbrugge; University Medical Center Utrecht, Utrecht, NL:
MG Ausems; Amsterdam Medical Center, NL: CM Aalfs; VU University Medical
Center, Amsterdam, NL: JJP Gille, Q Waisfisz, HEJ Meijers-Heijboer; University
Hospital Maastricht, Maastricht, NL: EB Gomez-Garcia, CE van Roozendaal,
Marinus J Blok, B Caanen; University Medical Center Groningen University,
NL: JC Oosterwijk, AH van der Hout, MJ Mourits; The Netherlands
Foundation for the detection of hereditary tumours, Leiden, NL: HF Vasen.
The HEBON study is supported by the Dutch Cancer Society grants NKI1998-
1854, NKI2004-3088, NKI2007-3756 and the ZonMW grant 91109024.
Helsinki Breast Cancer Study (HEBCS)
HEBCS acknowledge Drs. Kirsimari Aaltonen, Carl Blomqvist and Päivi Heikkilä
and research nurse Irja Erkkilä for their help with the patient data and
samples. The HEBCS study has been financially supported by the Helsinki
University Central Hospital Research Fund, Academy of Finland (132473), the
Finnish Cancer Society, and the Sigrid Juselius Foundation.
Interdisciplinary Health Research International Team Breast Cancer
Susceptibility (INHERIT BRCAs)
We would like to thank Martine Tranchant for skillful technical assistance. J.S.
is Chairholder of the Canada Research Chair in Oncogenetics. This work was
supported by the Canadian Institutes of Health Research for the “CIHR Team
in Familial Risks of Breast Cancer” program and by the Canadian Breast
Cancer Research Alliance-grant #019511.
Mulligan et al. Breast Cancer Research 2011, 13:R110
http://breast-cancer-research.com/content/13/6/R110
Page 15 of 20
ILUH
The ILUH group was supported by the Icelandic Association “Walking for
Breast Cancer Research” and by the Landspitali University Hospital Research
Fund.
Istituto Oncologico Veneto Hereditary Breast and Ovarian Cancer Study
(IOVHBOCS)
This study was supported by “Ministero della Salute” ("Progetto Tumouri
Femminili and grant numbers RFPS 2006-5-341353, ACC2/R6.9”)
Kathleen Cuningham Consortium for Research into Familial Breast Cancer
(kConFab)
We wish to thank Heather Thorne, Eveline Niedermayr, all the kConFab
research nurses and staff, the heads and staff of the Family Cancer Clinics,
and the Clinical Follow Up Study (funded 2001-2009 by NHMRC and
currently by the National Breast Cancer Foundation and Cancer Australia
#628333) for their contributions to this resource, and the many families who
contribute to kConFab. kConFab is supported by grants from the National
Breast Cancer Foundation, the National Health and Medical Research Council
(NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New
South Wales, Victoria, Tasmania and South Australia, and the Cancer
Foundation of Western Australia. ABS and GCT are NHMRC Fellows.
Mayo Clinic Study
The MAYO study was supported by NIH grants CA116167, CA128978, a
Specialized Program of Research Excellence (SPORE) in Breast Cancer
(CA116201), and awards from the Komen Foundation for the Cure and the
Breast Cancer Research Foundation.
Memorial Sloan-Kettering Cancer Center (MSKCC)
The study is supported by grant from the Breast Cancer Research
Foundation, Starr Cancer Consortium, Norman and Carol Stone Genetic
Research Fund, The Robert and Kate Niehaus Clinical Genetics Initiative at
MSKCC
National Cancer Institute study (NCI)
The research of Drs. PL Mai and MH Greene was supported by the
Intramural Research Program of the US National Cancer Institute, and by
support services contracts NO2-CP-11019-50 and N02-CP-65504 with Westat,
Inc., Rockville, MD.
N.N. Petrov Institute of Oncology
This work has been supported by the Russian Federation for Basic Research
(grants 10-04-92601, 10-04-92110, 11-04-00227), the Federal Agency for
Science and Innovations (contract 02.740.11.0780), the Commission of the
European Communities (grant PITN-GA-2009-238132) and through a Royal
Society International Joint grant (JP090615).
Ontario Cancer Genetics Network (OCGN)
We wish to thank Mona Gill, Lucine Collins, Nalan Gokgoz, Teresa Selander,
Nayana Weerasooriya and members of the Ontario Cancer Genetics Network
for their contributions to the study.
The Ohio State University Comprehensive Cancer Center (OSU-CCG)
This work was supported by the Ohio State University Comprehensive
Cancer Center. We thank Kevin Sweet and Leigha Senter for accrual of study
participants and data management. The Human Genetics Sample bank
prepared DNA samples and the OSU Nucleic Acids Shared Resource assisted
with genotyping.
Swedish BRCA1 and BRCA2 study (SWE-BRCA)
SWE-BRCA collaborators: Margareta Nordling, Annika Bergman and Zakaria
Einbeigi, Gothenburg, Sahlgrenska University Hospital; Sigrun Liedgren,
Linköping University Hospital; Åke Borg, Niklas Loman, Håkan Olsson, Ulf
Kristoffersson, Helena Jernström, Katja Harbst, Lund University Hospital;
Annika Lindblom, Annelie Liljegren, Gisela Barbany-Bustinza and Johanna
Rantala, Stockholm, Karolinska University Hospital; Beatrice Melin, Henrik
Grönberg, Eva-Lena Stattin and Monica Emanuelsson, Umeå University
Hospital; Hans Ehrencrona, Richard Rosenquist and Niklas Dahl, Uppsala
University Hospital.
University California San Francisco (UCSF)
The study received funding from the NIH, NCI Bay Area Breast Cancer SPORE
(P50 CA 058207) and the Avon Foundation. We acknowledge support from
the UCSF Helen Diller Family Comprehensive Cancer Center
UK and Gilda Radner Familial Ovarian Cancer Registries (UKGRFOCR)
UKFOCR was supported by a project grant from CRUK to Paul Pharoah. We
thank Simon Gayther, Carole Pye, Patricia Harrington and Eva Wozniak for
their contributions towards the UKFOCR. We’d like to acknowledge the
Roswell Park Alliance Foundation for their continued support of the Gilda
Radner Ovarian Family Cancer Registry. GRFOCR would like to acknowledge
Lara Sucheston (Department of Cancer Prevention and Control) and Kunle
Odunsi (Departments Gynecologic Oncology and Immunology).
University of Pennsylvania (UPENN)
Work is supported by grants from the Breast Cancer Research Foundation
(to KLN), MacDonald Family Foundation (SMD) and Komen Foundation
(SMD)
Author details
1Department of Laboratory Medicine and Pathobiology, University of
Toronto, Toronto, ON M5S 1A8, Canada; Department of Laboratory Medicine,
and the Keenan Research Centre of the Li Ka Shing Knowledge Institute, St
Michael’s Hospital, 30 Bond Street, Toronto, ON M5B 1W8, Canada.
2Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First
Street SW, Rochester, MN 55905, USA. 3Centre for Cancer Genetic
Epidemiology, Department of Public Health and Primary Care, University of
Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK. 4Department of
Medicine, Abramson Cancer Center, Perelman School of Medicine at the
University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA
19104, USA. 5Faculty of Medicine, University of Southampton, University
Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton,
SO16 6YD, UK. 6Department of Obstetrics and Gynecology, University of
Helsinki and Helsinki University Central Hospital, Haartmaninkatu 8, 00290
Helsinki, Finland. 7Department of Preventive Medicine, Keck School of
Medicine, University of Southern California, 2001 N Soto Street, Los Angeles,
CA 90089-9237, USA. 8Department of Medicine, Memorial Sloan-Kettering
Cancer Center and Weill Cornell Medical College, 1275 York Ave, New York,
NY 10065, USA. 9National Cancer Institute, Division of Cancer Epidemiology
and Genetics, Hormonal and Reproductive Epidemiology Branch, 6120
Executive Blvd., Rockville, MD 20852, USA. 10Queensland Institute of Medical
Research, 300 Herston Rd, Herston, Brisbane, QLD 4006, Australia. 11Centre of
Familial Breast and Ovarian Cancer, Department of Gynaecology and
Obstetrics and Centre for Integrated Oncology (CIO), University Hospital of
Cologne, Kerpener Str. 62, Cologne, 50931, Germany. 12Unité Mixte de
Génétique Constitutionnelle des Cancers Fréquents, Centre Hospitalier
Universitaire de Lyon/Centre Léon Bérard, 28 rue Laënnec, Lyon 69373,
France. 13INSERM U1052, CNRS UMR5286, Université Lyon 1, Cancer Research
Center of Lyon, 28 rue Laënnec, Lyon 69373, France. 14Department of
Molecular and Regenerative Medicine, Hematology, Oncology and
Transfusion Medicine Center, Vilnius University Hospital Santariskiu Clinics,
Santariskiu st 2, LT-08661 Vilnius and State Research Institute Innovative
Medicine Center, Zygimantu st. 9, LT-01102 Vilnius, Lithuania. 15Center for
Genomic Medicine, Rigshospitalet, Copenhagen University Hospital,
Blegdamsvej 9, DK-2100 Copenhagen, Denmark. 16Department of Oncology,
Rigshospitalet Bldg. 4262, Copenhagen University Hospital, Blegdamsvej 9,
DK-2100 Copenhagen, Denmark. 17Human Genetics Group, Human Cancer
Genetics Programme, Spanish National Cancer Research Centre, C/Melchor
Fernández Almagro 3, Madrid, 28029, Spain and the Spanish Network on
Rare Diseases (CIBERER). 18Institute of Biology and Molecular Genetics,
Universidad de Valladolid (IBGM-UVA), C/Sanz y Forés, N° 3, Valladolid, 47003,
Spain. 19Instituto de investigación sanitaria de Aragón (IIS), Hospital clinico
Universitario “Lozano Blesa”, San Juan Bosco 15, Zaragoza, 50009, Spain.
20Molecular Diagnostics Laboratory, IRRP, National Center for Scientific
Research Demokritos, Patriarchou Gregoriou E’ & Neapoleos Str, Ag. Paraskevi
15310, Athens, Greece. 21Human Genetics Group and Genotyping Unit,
Human Cancer Genetics Programme, Spanish National Cancer Research
Centre, C/Melchor Fernández Almagro 3, Madrid, 28029, Spain and the
Spanish Network on Rare Diseases (CIBERER). 22Unit of Molecular Bases of
Genetic Risk and Genetic Testing, Department of Preventive and Predictive
Medicine, Fondazione IRCCS Istituto Nazionale Tumouri (INT), via Giacomo
Venezian 1, 20133 Milan, Italy; IFOM, Fondazione Istituto FIRC di Oncologia
Molecolare, via Adamello 16, 20139 Milan, Italy. 23Unit of Medical Genetics,
Department of Preventive and Predictive Medicine, Fondazione IRCCS
Istituto Nazionale Tumouri (INT), via Giacomo Venezian 1, Milan, 20133, Italy.
24Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia,
via Ripamonti 435, Milan, 20141, Italy. 25Unit of Experimental Oncology 1,
Centro di Riferimento Oncologico, IRCCS, Aviano (PN), Italy. 26Department of
Genetics, Biology and BiochemIstry, University of Turin, Turin, Italy. 27Medical
Genetics Unit, Department of Clinical Physiopathology, University of
Florence, Firenze, Italy. 28Department of Molecular Medicine, “Sapienza”
University of Rome, Rome, Italy. 29Division of Medical Oncology, Regina
Elena Cancer Institute, Rome, Italy. 30Department of Experimental Oncology,
Mulligan et al. Breast Cancer Research 2011, 13:R110
http://breast-cancer-research.com/content/13/6/R110
Page 16 of 20
Istituto Europeo di Oncologia. Milan, Italy; Consortium for Genomics
Technology (Cogentech), Milan, Italy. 31Molecular Genetics of Breast Cancer,
Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.
32Department of Epidemiology, Netherlands Cancer Institute, Amsterdam,
The Netherlands. 33Department of Clinical Genetics, VU Medical Center,
Amsterdam, The Netherlands. 34Department of Human Genetics and
Department of Clinical Genetics, Leiden University Medical Center, Leiden,
The Netherlands. 35Department of Clinical Genetics and GROW, School for
Oncology and Developmental Biology, MUMC, Maastricht, The Netherlands.
36Department of Human Genetics 849, Radboud University Nijmegen
Medical Centre, P.O. BOX 9101, 6500 HB Nijmegen, The Netherlands.
37Department of Human Genetics 836, Radboud University Nijmegen
Medical Centre, P.O. BOX 9101, 6500 HB Nijmegen, The Netherlands.
38Department of Medical Oncology, Family Cancer Clinic, Erasmus University
Medical Center, Rotterdam, The Netherlands. 39Department of Surgical
Oncology, Family Cancer Clinic, Erasmus University Medical Center,
Rotterdam, The Netherlands. 40Department of Medical Genetics, University
Medical Center Utrecht, The Netherlands. 41Department of Clinical Genetics,
Academic Medical Center, Amsterdam, The Netherlands. 42Barts Cancer
Institute, Queen Mary University of London, Centre for Tumour Biology,
Charterhouse Square, London, UK. 43Genetic Medicine, Manchester Academic
Health Sciences Centre, Central Manchester University Hospitals NHS
Foundation Trust, Manchester, UK. 44Oncogenetics Team, The Institute of
Cancer Research and Royal Marsden NHS Foundation Trust, UK. 45Clinical
Genetics, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK.
46Yorkshire Regional Genetics Service, Leeds, UK. 47Ferguson-Smith Centre
for Clinical Genetics, Yorkhill Hospitals, Glasgow, UK. 48Sheffield Clinical
Genetics Service, Sheffield Children’s Hospital, Sheffield, UK. 49Clinical
Genetics Department, St Michael’s Hospital, Bristol, UK. 50North West Thames
Regional Genetics Service, Kennedy-Galton Centre, Harrow, UK. 51North of
Scotland Regional Genetics Service, NHS Grampian and University of
Aberdeen, Foresterhill, Aberdeen, UK. 52Nottingham Clinical Genetics Service,
Nottingham University Hospitals NHS Trust, UK. 53Cheshire and Merseyside
Clinical Genetics Service, Liverpool Women’s NHS Foundation Trust,
Liverpool, UK. 54Leicestershire Clinical Genetics Service, University Hospitals
of Leicester NHS Trust, UK. 55North East Thames Regional Genetics Service,
Great Ormond Street Hospital for Children NHS Trust, London, UK. 56All
Wales Medical Genetics Service, Glan Clwyd Hospital, Rhyl, UK. 57All Wales
Medical Genetics Services, Singleton Hospital, Swansea, UK. 58Department of
Pathology and Laboratory Medicine, University of Kansas Medical Center,
Kansas City, KS, USA. 59Institute for Medical Informatics, Statistics and
Epidemiology, University of Leipzig, Leipzig, Germany. 60Department of
Gynaecology and Obstetrics, Division of Tumour Genetics, Klinikum rechts
der Isar, Technical University, Munich, Germany. 61Department of
Gynaecology and Obstetrics, Ludwig-Maximillians University, Munich,
Germany. 62Department of Gynaecology and Obstetrics, University Hospital
of Schleswig-Holstein (UKSH), Campus Kiel, Christian-Albrechts University,
Kiel, Germany. 63Department of Gynaecology and Obstetrics, University
Hospital Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany.
64Institute of Human Genetics, Department of Human Genetics, Heidelberg
University Hospital, Heidelberg, Germany. 65Department of Gynaecology and
Obstetrics, University Hospital, Ulm, Germany. 66Institute of Cell and
Molecular Pathology, Hannover Medical School, Hannover, Germany.
67Department of Gynaecology and Obstetrics, University Hospital Carl Gustav
Carus, Technical University, Dresden, Germany. 68Institute of Human
Genetics, University of Münster, Münster, Germany. 69Institute of Human
Genetics, Campus Virchov Klinikum, Charite Berlin, Germany. 70Centre of
Familial Breast and Ovarian Cancer, Department of Medical Genetics,
Institute of Human Genetics, University Würzburg, Germany. 71Institute of
Human Genetics, University Regensburg, Germany. 72Institute of Human
Genetics, University Leipzig, Germany. 73Institute of Human Genetics,
University Hospital, Frankfurt a.M., Germany. 74Breakthrough Breast Cancer
Research Centre, Institute of Cancer Research, UK. 75Service de Génétique
Oncologique, Institut Curie, Paris, France. 76Genetic Unit, Avicenne Hospital,
Assitance Publique-Hôpitaux de Paris, Paris, France; Sud-Francilien Hospital,
Evry-Corbeil, France; University Hospital, Clermont-Ferrand, France. 77Centre
François Baclesse, Caen, France. 78Unité d’Oncogénétique, CLCC Paul Strauss,
Strasbourg, France. 79Service de Génétique, Centre Hospitalier Universitaire
Bretonneau, Tours, France. 80Unité d’Oncogénétique, CHU Arnaud de
Villeneuve, Montpellier, France. 81Service de Génétique Clinique
Chromosomique et Moléculaire, Centre Hospitalier Universitaire de St
Etienne, St Etienne, France. 82Cancer Genetics Unit, INSERM U916, Institut
Bergonié, Université de Bordeaux, Bordeaux, France. 83Unité INSERM U830,
Institut Curie, Paris, France; Université Paris Descartes, Faculté de Médecine,
Paris, France. 84Lombardi Comprehensive Cancer Center, Georgetown
University, Washington DC, USA. 85Molecular Oncology Laboratory, Hospital
Clinico San Carlos, Madrid, Spain. 86Department of Clinical Genetics, Helsinki
University Central Hospital, Meilahdentie 2, 00290 Helsinki, Finland.
87Hereditary Cancer Program, Institut Català d’Oncologia, Hospital Duran i
Reynals - Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de
Llobregat, Barcelona, Spain. 88Department of Pathology, Landspitali
University Hospital, Reykjavik, Iceland, Faculty of Medicine, University of
Iceland, Reykjavik, Iceland. 89Cancer Genomics Laboratory, Centre Hospitalier
Universitaire de Québec, 2705 Laurier Boulevard, T3-57, Quebec City, QC,
Canada. 90Cancer Genomics Laboratory, Centre Hospitalier Universitaire de
Québec, 2705 Laurier Boulevard, T3-57, Quebec City, QC, Canada; Canada
Research Chair in Oncogenetics, Department of Molecular Medicine, Faculty
of Medicine, Laval University, QC, Canada. 91Immunology and Molecular
Oncology Unit, Istituto Oncologico Veneto IOV - IRCCS, Via Gattamelata 64,
35128 Padua, Italy. 92Department of Oncology and Surgical Sciences,
University of Padua and Istituto Oncologico Veneto IOV - IRCCS, Via
Gattamelata 64, 35128 Padua, Italy. 93Peter MacCallum Cancer Centre,
Melbourne, VIC 3052, Australia. 94Department of Anatomical Pathology,
Prince of Wales Hospital, Randwick, NSW 2031, Australia. 95Abramson Cancer
Center and University of Pennsylvania Perelman School of Medicine,
Philadelphia, PA, USA. 96University of Chicago, Chicago, IL, USA. 97City of
Hope Comprehensive Cancer Center and Department of Population
Sciences, Beckman Research Institute, City of Hope, Duarte, CA, USA.
98Departments of Medicine, and Preventive Medicine and Public Health,
Creighton University, Omaha, NE, USA. 99Jonsson Comprehensive Cancer
Center at the University of California, Los Angeles, CA, USA. 100Department
of Internal Medicine and Harold C. Simmons Comprehensive Cancer Center,
University of Texas, Southwestern Medical Center, Dallas, TX; USA;
Department of Pediatrics, University of Texas Health Science Center at San
Antonio, San Antonio, TX, USA. 101Department of Health Sciences Research,
Mayo Clinic, Rochester, MN, USA. 102Department of Medical Genetics, Mayo
Clinic, Rochester, MN, USA. 103University of Delaware, Newark, DE, USA.
104Epidemiology Research Program, American Cancer Society, Atlanta, GA,
USA. 105Department of Obstetrics/Gynaecology and Comprehensive Cancer
Center, Medical University of Vienna, Vienna, Austria. 106Clinical Genetics
Branch, Division of Cancer Epidemiology and Genetics, US National Cancer
Institute, Rockville, MD, USA. 107Laboratory of Molecular Oncology, N.N.
Petrov Institute of Oncology, St.-Petersburg, Russia. 108Department of
Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON,
Canada; Department of Laboratory Medicine, and the Keenan Research
Centre of the Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto,
ON, Canada. 109Samuel Lunenfeld Research Institute, Mount Sinai Hospital,
Toronto; Department of Laboratory Medicine and Pathobiology, University of
Toronto, ON, Canada. 110Cancer Care Ontario, ON, Canada. 111Departments
of Molecular Virology, Immunology and Medical Genetics and Internal
Medicine, The Ohio State University Comprehensive Cancer Center,
Columbus, OH, USA. 112Clinical Genetics, Rigshospital, Copenhagen
University, Copenhagen, Denmark. 113Clinical Genetics, Odense University
Hospital, Odense, Denmark. 114Department of Clinical Genetics, Aarhus
University Hospital, Aarhus, Denmark. 115Clinical Genetics, Vejle Hospital,
Denmark. 116Section of Genetic Oncology, Dept. of Laboratory Medicine,
University and University Hospital of Pisa, Pisa, Italy. 117Department of Clinical
Genetics, Lund University Hospital, Lund, Sweden. 118Oncological Centre,
Lund University Hospital, Lund, Sweden. 119Department of Oncology,
Karolinska University Hospital, Stockholm, Sweden. 120Division of Clinical
Genetics, Department of Clinical and Experimental Medicine, Linköping
University, Linköping, Sweden. 121Department of Oncology, Sahlgrenska
University Hospital, Gothenburg, Sweden. 122Department of Population
Sciences, the Beckman Research Institute of the City of Hope, Duarte, CA,
USA. 123UCSF Cancer Risk Program and Departments of Medicine and
Epidemiology and Biostatistics, University of California San Francisco, San
Francisco, CA, USA. 124Department of Oncology, University of Cambridge,
Cambridge, UK. 125Department of Cancer Prevention and Control, Roswell
Park Cancer Institute, Buffalo, NY, USA. 126Women’s Cancer Program at the
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center,
Los Angeles, CA, USA. 127Department of Epidemiology, Cancer Prevention
Institute of California, Fremont, CA, USA. 128Fox Chase Cancer Center,
Mulligan et al. Breast Cancer Research 2011, 13:R110
http://breast-cancer-research.com/content/13/6/R110
Page 17 of 20
Philadelphia, PA, USA. 129Department of Oncological Sciences, Huntsman
Cancer Institute, University of Utah, Salt Lake City, UT, USA. 130Genetic
Epidemiology Laboratory, Department of Pathology, University of Melbourne,
Melbourne, VIC, Australia. 131Centre for Molecular, Environmental, Genetic
and Analytic Epidemiology, University of Melbourne, Melbourne, VIC,
Australia. 132Department of Epidemiology, Columbia University, New York,
NY, USA. 133Department of Cancer Biology, Dana-Farber Cancer Institute,
Boston, MA, USA. 134Department of Dermatology, University of Utah School
of Medicine, Salt Lake City, UT, USA. 135Samuel Lunenfeld Research Institute,
Mount Sinai Hospital, 600 University Avenue, Toronto, ON, M5G 1X5, Canada;
Cancer Care Ontario, Departments of Molecular Genetics and Laboratory
Medicine and Pathobiology, University of Toronto, ON, Canada. 136Breast
Cancer Family Registry. 137Cancer Genetics Network “Groupe Génétique et
Cancer”, Fédération Nationale des Centres de Lutte Contre le Cancer.
138Netherlands Cancer Institute, Amsterdam, The Netherlands. 139Ontario
Cancer Genetics Network, Cancer Care Ontario, 620 University Avenue,
Toronto, ON M5G 2L7, Canada. 140Karolinska Institute, Stockholm, Sweden.
Authors’ contributions
AMM, ILA, ACA drafted the initial manuscript. ACA developed the analytical
methods and performed the statistical analysis. AMM, ACA, ILA, FJC, DB,
SMD, DE, HN, SJR, MR, MS, ABS and BW are members of the CIMBA
pathology working group and participated in the design of the study. LM
and DB are the CIMBA database managers. AL wrote computer programs for
the analysis. SH and OMS reviewed, recoded and classified the BRCA1 and
BRCA2 mutations in CIMBA. GCT initiated and coordinated CIMBA. DFE
participated in the study design and advised on the statistical analysis. RJ,
TvOH, FCNi, BE, AO, IMR, MD, JG, MP, JB, PP, SM, BP, DZ, EC, BB, AV, BP, LP,
LO, AS, LB, PR, UH, MV, HEJMH, JW, EBGG, MRN, MK, CS, MMATL, RBvdL, TvO,
MR, DF, JLJ, DGE, FL, RE, LI, JA, RD, JC, AD, HD, HG, JE, CH, JB, LES, E McC,
AM, SP, AG, RKS, KR, CE, AM, IR, NA, DN, CS, HD, DG, KK, SPA, RVM, IS, BF,
WH, DS, HG, VCM, FCFC, SM, ML, NBK, AH, PB, DM, JPF, IM, PP, IC, ML, CK,
ML, NS, DSL, CI, TC, MH, TH, KA,IB, CL, RBB, PS, MD, JS, MM, ST, EDA, SF, MY,
TR, OO, JNW, HTL, PAG, GET, XW, ZF, VSP, NML, CS, KO, RS, MG, JB, NK, CFS,
MKT, DGK, AFR, PLM, MHG, EI, FPO, HO, GG, AET, AMG, MT, TAK, UBJ, ABS,
MAC, MS, KH, AvW, BA, MSA, PK, YCD, SLN, MB, PDPP, KBM, KLN, BYK, JG,
EMJ, MJD, SMB, MCS, JLH, MBT, WC, AFM and DG acquired phenotypic data
and DNA samples or performed SNP genotyping. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 27 April 2011 Accepted: 2 November 2011
Published: 2 November 2011
References
1. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE: Risks of cancer in
BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994,
343:692-695.
2. The Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation
carriers. J Natl Cancer Inst 1999, 91:1310-1316.
3. Thompson D, Easton DF: Cancer incidence in BRCA1 mutation carriers. J
Natl Cancer Inst 2002, 94:1358-1365.
4. Mavaddat N, Pharoah PD, Blows F, Driver KE, Provenzano E, Thompson D,
Macinnis RJ, Shah M, Easton DF, Antoniou AC: Familial relative risks for
breast cancer by pathological subtype: a population-based cohort study.
Breast Cancer Res 2010, 12:R10.
5. Thompson D, Easton D: The genetic epidemiology of breast cancer
genes. J Mammary Gland Biol Neoplasia 2004, 9:221-236.
6. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL,
Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S,
Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J,
Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H,
Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, et al: Average
risks of breast and ovarian cancer associated with BRCA1 or BRCA2
mutations detected in case Series unselected for family history: a
combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130.
7. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC,
Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M,
Liang X, Hummer AJ, Sima C, Bernstein JL: Variation of breast cancer risk
among BRCA1/2 carriers. JAMA 2008, 299:194-201.
8. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT,
Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J,
Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S,
Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-
Hedman M, et al: Genetic heterogeneity and penetrance analysis of the
BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer
Linkage Consortium. Am J Hum Genet 1998, 62:676-689.
9. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR,
Easton DF, Venter DJ: Population-based estimate of the average age-
specific cumulative risk of breast cancer for a defined set of protein-
truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer
Family Study. Cancer Epidemiol Biomarkers Prev 1999, 8:741-747.
10. Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Diez O,
Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A,
Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI,
Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San
Román C, Antoniou AC, Urioste M, Benítez J: The average cumulative risks
of breast and ovarian cancer for carriers of mutations in BRCA1 and
BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 2008,
14:2861-2869.
11. Simchoni S, Friedman E, Kaufman B, Gershoni-Baruch R, Orr-Urtreger A,
Kedar-Barnes I, Shiri-Sverdlov R, Dagan E, Tsabari S, Shohat M, Catane R,
King MC, Lahad A, Levy-Lahad E: Familial clustering of site-specific cancer
risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi
Jewish population. Proc Natl Acad Sci USA 2006, 103:3770-3774.
12. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M,
Timmerman MM, Brody LC, Tucker MA: The risk of cancer associated with
specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J
Med 1997, 336:1401-1408.
13. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S,
Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE,
Brown PO, Børresen-Dale AL, Botstein D: Repeated observation of breast
tumour subtypes in independent gene expression data sets. Proc Natl
Acad Sci USA 2003, 100:8418-8423.
14. van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL,
van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM,
Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling
predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
15. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de
Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM,
Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W,
McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D,
Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JG, Devilee P, et al:
Multifactorial analysis of differences between sporadic breast cancers
and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst
1998, 90:1138-1145.
16. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M,
Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U,
Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Krämling C, Daly PA,
Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG,
Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, et al:
Prediction of BRCA1 status in patients with breast cancer using estrogen
receptor and basal phenotype. Clin Cancer Res 2005, 11:5175-5180.
17. Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, Giles G,
Godwin AK, Hibshoosh H, Hopper JL, John EM, Layfield L, Longacre T,
Miron A, Senie R, Southey MC, West DW, Whittemore AS, Wu H, Andrulis IL,
O’Malley FP: BRCA2 mutation-associated breast cancers exhibit a
distinguishing phenotype based on morphology and molecular profiles
from tissue microarrays. Am J Surg Pathol 2007, 31:121-128.
18. Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK, Platte R,
Morrison J, Maranian M, Pooley KA, Luben R, Eccles D, Evans DG,
Fletcher O, Johnson N, dos Santos Silva I, Peto J, Stratton MR, Rahman N,
Jacobs K, Prentice R, Anderson GL, Rajkovic A, Curb JD, Ziegler RG, Berg CD,
Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, et al: Newly
discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat
Genet 2009, 41:585-590.
19. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D,
Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N,
Ahmed S, Healey CS, Bowman R, SEARCH collaborators, Meyer KB,
Mulligan et al. Breast Cancer Research 2011, 13:R110
http://breast-cancer-research.com/content/13/6/R110
Page 18 of 20
Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P,
Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D,
Evans DG, Peto J, et al: Genome-wide association study identifies novel
breast cancer susceptibility loci. Nature 2007, 447:1087-1093.
20. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE,
Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N,
Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA,
Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS,
Fraumeni JF Jr, Hoover RN, Thomas G, Chanock SJ: A genome-wide
association study identifies alleles in FGFR2 associated with risk of
sporadic postmenopausal breast cancer. Nat Genet 2007, 39:870-874.
21. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J,
Gudjonsson SA, Masson G, Jakobsdottir M, Thorlacius S, Helgason A,
Aben KK, Strobbe LJ, Albers-Akkers MT, Swinkels DW, Henderson BE,
Kolonel LN, Le Marchand L, Millastre E, Andres R, Godino J, Garcia-Prats MD,
Polo E, Tres A, Mouy M, Saemundsdottir J, Backman VM, Gudmundsson L,
Kristjansson K, Bergthorsson JT, Kostic J, et al: Common variants on
chromosomes 2q35 and 16q12 confer susceptibility to estrogen
receptor-positive breast cancer. Nat Genet 2007, 39:865-869.
22. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF,
Jakobsdottir M, Bergthorsson JT, Gudmundsson J, Aben KK, Strobbe LJ,
Swinkels DW, van Engelenburg KC, Henderson BE, Kolonel LN, Le
Marchand L, Millastre E, Andres R, Saez B, Lambea J, Godino J, Polo E,
Tres A, Picelli S, Rantala J, Margolin S, Jonsson T, Sigurdsson H, Jonsdottir T,
Hrafnkelsson J, et al: Common variants on chromosome 5p12 confer
susceptibility to estrogen receptor-positive breast cancer. Nat Genet
2008, 40:703-706.
23. Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG,
Hankinson SE, Hutchinson A, Wang Z, Yu K, Chatterjee N, Garcia-Closas M,
Gonzalez-Bosquet J, Prokunina-Olsson L, Orr N, Willett WC, Colditz GA,
Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ,
Diver R, Prentice R, Jackson R, Kooperberg C, Chlebowski R, Lissowska J,
et al: A multistage genome-wide association study in breast cancer
identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat
Genet 2009, 41:579-584.
24. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S,
Ghoussaini M, Hines S, Healey CS, Hughes D, Warren-Perry M, Tapper W,
Eccles D, Evans DG, Breast Cancer Susceptibility Collaboration (UK),
Hooning M, Schutte M, van den Ouweland A, Houlston R, Ross G,
Langford C, Pharoah PD, Stratton MR, Dunning AM, Rahman N, Easton DF:
Genome-wide association study identifies five new breast cancer
susceptibility loci. Nat Genet 2010, 42:504-507.
25. Zeger SL, Liang KY, Albert PS: Models for longitudinal data: a generalized
estimating equation approach. Biometrics 1988, 44:1049-1060.
26. Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS,
Apicella C, Smith LD, Hammet F, Southey MC, Van ‘t Veer LJ, de Groot R,
Smit VT, Fasching PA, Beckmann MW, Jud S, Ekici AB, Hartmann A, Hein A,
Schulz-Wendtland R, Burwinkel B, Marme F, Schneeweiss A, Sinn HP,
Sohn C, Tchatchou S, Bojesen SE, Nordestgaard BG, Flyger H, Ørsted DD,
et al: Low penetrance breast cancer susceptibility loci are associated
with specific breast tumour subtypes: findings from the Breast Cancer
Association Consortium. Hum Mol Genet 2011, 20:3289-3303.
27. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA,
Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G,
González-Neira A, Benítez J, Zamora P, Brauch H, Justenhoven C,
Hamann U, Ko YD, Bruening T, Haas S, Dörk T, Schürmann P, Hillemanns P,
Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittomäki K,
et al: Heterogeneity of breast cancer associations with five susceptibility
Loci by clinical and pathological characteristics. PLoS Genet 2008, 4:
e1000054.
28. Antoniou AC, Kartsonaki C, Sinilnikova O, Soucy P, McGuffog L, Healey S,
Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E,
Barile M, Pensotti V, Pasini B, Dolcetti R, Giannini G, Putignano AL,
Varesco L, Radice P, Mai PL, Greene MH, Andrulis IL, Glendon G, Ozcelik H,
Thomassen M, Gerdes AM, Kruse TA, Birk Jensen U, Crüger DG, et al:
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer
risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2011,
20:3304-3321.
29. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA,
Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W,
Sutter C, Niederacher D, Deissler H, Caldes T, Kämpjärvi K, Nevanlinna H,
Simard J, Beesley J, Chen X, Kathleen Cuningham Consortium for Research
into Familial Breast Cancer, Neuhausen SL, Rebbeck TR, Wagner T,
Lynch HT, Isaacs C, Weitzel J, Ganz PA, Daly MB, Tomlinson G, et al:
Common breast cancer-predisposition alleles are associated with breast
cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008,
82:937-948.
30. Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H,
Heikkinen T, Simard J, Spurdle AB, Beesley J, Chen X, Kathleen Cuningham
Foundation Consortium for Research into Familial Breast Cancer,
Neuhausen SL, Ding YC, Couch FJ, Wang X, Fredericksen Z, Peterlongo P,
Peissel B, Bonanni B, Viel A, Bernard L, Radice P, Szabo CI, Foretova L,
Zikan M, Claes K, Greene MH, Mai PL, Rennert G, Lejbkowicz F, et al:
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for
BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2009, 18:4442-4456.
31. Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S,
Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C,
Ganz PA, Tomlinson G, Olopade OI, Couch FJ, Wang X, Lindor NM,
Pankratz VS, Radice P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Viel A,
Allavena A, Dall’Olio V, Peterlongo P, Szabo CI, Zikan M, Claes K, et al:
Common breast cancer susceptibility alleles and the risk of breast
cancer for BRCA1 and BRCA2 mutation carriers: implications for risk
prediction. Cancer Res 2010, 70:9742-9754.
32. Reeves GK, Travis RC, Green J, Bull D, Tipper S, Baker K, Beral V, Peto R,
Bell J, Zelenika D, Lathrop M, Million Women Study Collaborators: Incidence
of breast cancer and its subtypes in relation to individual and multiple
low-penetrance genetic susceptibility loci. JAMA 2010, 304:426-434.
33. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF,
Goldgar DE: An international initiative to identify genetic modifiers of
cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of
Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer
Res 2007, 9:104.
34. 2011 [http://www.srl.cam.ac.uk/consortia/cimba/eligibility/eligibility.html].
35. Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R,
Rookus MA, Easton DF: A weighted cohort approach for analysing factors
modifying disease risks in carriers of high-risk susceptibility genes. Genet
Epidemiol 2005, 29:1-11.
36. Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M,
Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ,
Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ, Genetic Modifiers of
Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO), Rebbeck TR,
Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J,
Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A,
Lubinski J, et al: RAD51 135G–> C modifies breast cancer risk among
BRCA2 mutation carriers: results from a combined analysis of 19 studies.
Am J Hum Genet 2007, 81:1186-1200.
37. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D:
Evidence for further breast cancer susceptibility genes in addition to
BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 2001,
21:1-18.
38. Mavaddat N, Rebbeck TR, Lakhani SR, Easton DF, Antoniou AC:
Incorporating tumour pathology information into breast cancer risk
prediction algorithms. Breast Cancer Res 2010, 12:R28.
39. Lange K, Weeks D, Boehnke M: Programs for Pedigree Analysis: MENDEL,
FISHER, and dGENE. Genet Epidemiol 1988, 5:471-472.
40. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA,
Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O,
Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-
Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L,
Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, et al: The
BOADICEA model of genetic susceptibility to breast and ovarian cancers:
updates and extensions. Br J Cancer 2008, 98:1457-1466.
41. Boos DD: On generalised score tests. American Statistician 1992,
46:327-333.
42. Stacey SN, Sulem P, Zanon C, Gudjonsson SA, Thorleifsson G, Helgason A,
Jonasdottir A, Besenbacher S, Kostic JP, Fackenthal JD, Huo D,
Adebamowo C, Ogundiran T, Olson JE, Fredericksen ZS, Wang X, Look MP,
Sieuwerts AM, Martens JW, Pajares I, Garcia-Prats MD, Ramon-Cajal JM, de
Juan A, Panadero A, Ortega E, Aben KK, Vermeulen SH, Asadzadeh F, van
Engelenburg KC, Margolin S, et al: Ancestry-shift refinement mapping of
the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet 2010, 6:
e1001029.
Mulligan et al. Breast Cancer Research 2011, 13:R110
http://breast-cancer-research.com/content/13/6/R110
Page 19 of 20
43. Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, Wen W, Levy S,
Deming SL, Haines JL, Gu K, Fair AM, Cai Q, Lu W, Shu XO: Genome-wide
association study identifies a new breast cancer susceptibility locus at
6q25.1. Nat Genet 2009, 41:324-328.
44. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R,
Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M,
Barrowdale D, EMBRACE, Peock S, Cook M, Oliver C, Frost D, Eccles D,
Evans DG, Eeles R, Izatt L, Chu C, Douglas F, Paterson J, Stoppa-Lyonnet D,
Houdayer C, Mazoyer S, Giraud S, Lasset C, Remenieras A, et al: A locus on
19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is
associated with hormone receptor-negative breast cancer in the general
population. Nat Genet 2010, 42:885-892.
45. Milne RL, Benitez J, Nevanlinna H, Heikkinen T, Aittomaki K, Blomqvist C,
Arias JI, Zamora MP, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK,
Cox A, Brock I, Elliott G, Reed MW, Southey MC, Smith L, Spurdle AB,
Hopper JL, Couch FJ, Olson JE, Wang X, Fredericksen Z, Schürmann P,
Bremer M, Hillemanns P, Dörk T, Devilee P, van Asperen CJ, et al: Risk of
estrogen receptor-positive and -negative breast cancer and single-
nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst 2009,
101:1012-1018.
46. Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M: Genetic
susceptibility to breast cancer. Mol Oncol 2010, 4:174-191.
47. Wacholder S, Han SS, Weinberg CR: Inference from a multiplicative model
of joint genetic effects or ovarian cancer risk. J Natl Cancer Inst 2011,
103:82-83.
48. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S,
Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R,
Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A,
Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P,
Viale G, Visscher D, Wheeler T, Williams RB, et al: American Society of
Clinical Oncology/College of American Pathologists guideline
recommendations for immunohistochemical testing of estrogen and
progesterone receptors in breast cancer (unabridged version). Arch
Pathol Lab Med 2010, 134:e48-e72.
49. Collins LC, Botero ML, Schnitt SJ: Bimodal frequency distribution of
estrogen receptor immunohistochemical staining results in breast
cancer: an analysis of 825 cases. Am J Clin Pathol 2005, 123:16-20.
50. Milne RL, Antoniou AC: Genetic modifiers of cancer risk for BRCA1 and
BRCA2 mutation carriers. Ann Oncol 2011, 22(Suppl 1):i11-i17.
51. Fletcher O, Johnson N, Orr N, Hosking FJ, Gibson LJ, Walker K, Zelenika D,
Gut I, Heath S, Palles C, Coupland B, Broderick P, Schoemaker M, Jones M,
Williamson J, Chilcott-Burns S, Tomczyk K, Simpson G, Jacobs KB,
Chanock SJ, Hunter DJ, Tomlinson IP, Swerdlow A, Ashworth A, Ross G, dos
Santos Silva I, Lathrop M, Houlston RS, Peto J: Novel breast cancer
susceptibility locus at 9q31.2: results of a genome-wide association
study. J Natl Cancer Inst 2011, 103:425-435.
52. Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, Segre AV,
McGee K, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM,
Stoppa-Lyonnet D, Mazoyer S, Gauthier-Villars M, Sobol H, Longy M,
Frenay M, GEMO Study Collaborators, Hogervorst FB, Rookus MA, Collée JM,
Hoogerbrugge N, van Roozendaal KE, HEBON Study Collaborators,
Piedmonte M, Rubinstein W, Nerenstone S, Van Le L, et al: Common
genetic variants and modification of penetrance of BRCA2-associated
breast cancer. PLoS Genet 2010, 6:e1001183.
doi:10.1186/bcr3052
Cite this article as: Mulligan et al.: Common breast cancer susceptibility
alleles are associated with tumour subtypes in BRCA1 and BRCA2
mutation carriers: results from the Consortium of Investigators of
Modifiers of BRCA1/2. Breast Cancer Research 2011 13:R110.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mulligan et al. Breast Cancer Research 2011, 13:R110
http://breast-cancer-research.com/content/13/6/R110
Page 20 of 20
